US11241511B2 - HER3 peptides for imaging and radiotherapy - Google Patents
HER3 peptides for imaging and radiotherapy Download PDFInfo
- Publication number
- US11241511B2 US11241511B2 US16/475,020 US201716475020A US11241511B2 US 11241511 B2 US11241511 B2 US 11241511B2 US 201716475020 A US201716475020 A US 201716475020A US 11241511 B2 US11241511 B2 US 11241511B2
- Authority
- US
- United States
- Prior art keywords
- acid
- her3
- group
- natural derivative
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 title abstract description 150
- 238000003384 imaging method Methods 0.000 title abstract description 56
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 title abstract description 5
- 238000001959 radiotherapy Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 106
- 239000012216 imaging agent Substances 0.000 claims abstract description 19
- 150000001413 amino acids Chemical class 0.000 claims description 61
- 229910052698 phosphorus Inorganic materials 0.000 claims description 52
- 229910052717 sulfur Inorganic materials 0.000 claims description 52
- 235000001014 amino acid Nutrition 0.000 claims description 48
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- 229910052757 nitrogen Inorganic materials 0.000 claims description 26
- 229910052700 potassium Inorganic materials 0.000 claims description 26
- 238000012879 PET imaging Methods 0.000 claims description 23
- -1 89Zr Chemical compound 0.000 claims description 22
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 20
- 229910052799 carbon Inorganic materials 0.000 claims description 19
- 229910052720 vanadium Inorganic materials 0.000 claims description 17
- 239000002738 chelating agent Substances 0.000 claims description 12
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims description 11
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 claims description 8
- ABEIJMWLNYUWMD-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-5-[(4-isothiocyanatophenyl)methyl]-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(=O)O)CCN(CC(O)=O)CC1CC1=CC=C(N=C=S)C=C1 ABEIJMWLNYUWMD-UHFFFAOYSA-N 0.000 claims description 8
- 150000008574 D-amino acids Chemical class 0.000 claims description 8
- 150000008575 L-amino acids Chemical class 0.000 claims description 8
- CYJYKTMBMMYRHR-UHFFFAOYSA-N acetic acid;1,4,7-triazonane Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.C1CNCCNCCN1 CYJYKTMBMMYRHR-UHFFFAOYSA-N 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 claims description 6
- RAEOEMDZDMCHJA-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-[2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]ethyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CCN(CC(O)=O)CC(O)=O)CC(O)=O RAEOEMDZDMCHJA-UHFFFAOYSA-N 0.000 claims description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 6
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 6
- 229960001484 edetic acid Drugs 0.000 claims description 6
- 229960003330 pentetic acid Drugs 0.000 claims description 6
- 150000002500 ions Chemical class 0.000 claims description 5
- 230000005298 paramagnetic effect Effects 0.000 claims description 5
- GRUVVLWKPGIYEG-UHFFFAOYSA-N 2-[2-[carboxymethyl-[(2-hydroxyphenyl)methyl]amino]ethyl-[(2-hydroxyphenyl)methyl]amino]acetic acid Chemical compound C=1C=CC=C(O)C=1CN(CC(=O)O)CCN(CC(O)=O)CC1=CC=CC=C1O GRUVVLWKPGIYEG-UHFFFAOYSA-N 0.000 claims description 3
- JVHROZDXPAUZFK-UHFFFAOYSA-N TETA Chemical compound OC(=O)CN1CCCN(CC(O)=O)CCN(CC(O)=O)CCCN(CC(O)=O)CC1 JVHROZDXPAUZFK-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000006289 hydroxybenzyl group Chemical group 0.000 claims description 3
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 claims description 3
- 229960001124 trientine Drugs 0.000 claims description 3
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 56
- 238000002648 combination therapy Methods 0.000 abstract description 3
- 239000000700 radioactive tracer Substances 0.000 abstract 1
- 238000003325 tomography Methods 0.000 abstract 1
- 101001010819 Homo sapiens Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 152
- 108090000765 processed proteins & peptides Proteins 0.000 description 96
- 206010028980 Neoplasm Diseases 0.000 description 93
- 238000011282 treatment Methods 0.000 description 44
- 229920001184 polypeptide Polymers 0.000 description 40
- 102000004196 processed proteins & peptides Human genes 0.000 description 40
- 230000027455 binding Effects 0.000 description 39
- 241000699670 Mus sp. Species 0.000 description 33
- 239000003814 drug Substances 0.000 description 30
- 229940124597 therapeutic agent Drugs 0.000 description 26
- 230000003827 upregulation Effects 0.000 description 26
- 238000004458 analytical method Methods 0.000 description 24
- 230000014509 gene expression Effects 0.000 description 23
- 125000005647 linker group Chemical group 0.000 description 23
- 238000002600 positron emission tomography Methods 0.000 description 23
- 150000001875 compounds Chemical class 0.000 description 22
- 238000002560 therapeutic procedure Methods 0.000 description 20
- 238000000338 in vitro Methods 0.000 description 19
- 230000005764 inhibitory process Effects 0.000 description 19
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 18
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 18
- 229910052721 tungsten Inorganic materials 0.000 description 18
- 229910052727 yttrium Inorganic materials 0.000 description 18
- 201000011510 cancer Diseases 0.000 description 16
- 206010006187 Breast cancer Diseases 0.000 description 15
- 208000026310 Breast neoplasm Diseases 0.000 description 15
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 15
- 238000001727 in vivo Methods 0.000 description 15
- 229960004891 lapatinib Drugs 0.000 description 15
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 14
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 239000003112 inhibitor Substances 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 239000003981 vehicle Substances 0.000 description 14
- 238000001262 western blot Methods 0.000 description 14
- 150000003141 primary amines Chemical class 0.000 description 13
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 12
- 238000002626 targeted therapy Methods 0.000 description 12
- 125000003396 thiol group Chemical group [H]S* 0.000 description 12
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 12
- 206010060862 Prostate cancer Diseases 0.000 description 11
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 11
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 11
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 102000038030 PI3Ks Human genes 0.000 description 10
- 108091007960 PI3Ks Proteins 0.000 description 10
- 108091008611 Protein Kinase B Proteins 0.000 description 10
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 125000006239 protecting group Chemical group 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 239000012828 PI3K inhibitor Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 229920003356 PDX® Polymers 0.000 description 8
- 230000021615 conjugation Effects 0.000 description 8
- 239000003431 cross linking reagent Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 238000011002 quantification Methods 0.000 description 8
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 239000010949 copper Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- 238000003364 immunohistochemistry Methods 0.000 description 7
- 230000000977 initiatory effect Effects 0.000 description 7
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical group C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000007783 downstream signaling Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 102000034285 signal transducing proteins Human genes 0.000 description 6
- 108091006024 signal transducing proteins Proteins 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- GRZXWCHAXNAUHY-NSISKUIASA-N (2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]-1-piperazinyl]-3-(propan-2-ylamino)-1-propanone Chemical group C1([C@H](C(=O)N2CCN(CC2)C=2C=3[C@H](C)C[C@@H](O)C=3N=CN=2)CNC(C)C)=CC=C(Cl)C=C1 GRZXWCHAXNAUHY-NSISKUIASA-N 0.000 description 5
- 108010085238 Actins Proteins 0.000 description 5
- 229940126638 Akt inhibitor Drugs 0.000 description 5
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 5
- 229940125497 HER2 kinase inhibitor Drugs 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 238000004132 cross linking Methods 0.000 description 5
- 229910052805 deuterium Inorganic materials 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 239000003197 protein kinase B inhibitor Substances 0.000 description 5
- 125000006850 spacer group Chemical group 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000003656 tris buffered saline Substances 0.000 description 5
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 4
- UQXNEWQGGVUVQA-UHFFFAOYSA-N 8-aminooctanoic acid Chemical compound NCCCCCCCC(O)=O UQXNEWQGGVUVQA-UHFFFAOYSA-N 0.000 description 4
- 0 CCCCC*P[3H][K]F*SC Chemical compound CCCCC*P[3H][K]F*SC 0.000 description 4
- IIYFAKIEWZDVMP-UHFFFAOYSA-N CCCCCCCCCCCCC Chemical compound CCCCCCCCCCCCC IIYFAKIEWZDVMP-UHFFFAOYSA-N 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 125000005529 alkyleneoxy group Chemical group 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 229960002684 aminocaproic acid Drugs 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 230000005754 cellular signaling Effects 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 4
- 229960001433 erlotinib Drugs 0.000 description 4
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 4
- 239000003193 general anesthetic agent Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 238000012417 linear regression Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 229950010966 patritumab Drugs 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 4
- 229950008834 seribantumab Drugs 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
- RUVRGYVESPRHSZ-UHFFFAOYSA-N 2-[2-(2-azaniumylethoxy)ethoxy]acetate Chemical compound NCCOCCOCC(O)=O RUVRGYVESPRHSZ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- QZUFNKONEPLWBC-UHFFFAOYSA-N CC(C)(C)CCCCC(C)(C)C Chemical compound CC(C)(C)CCCCC(C)(C)C QZUFNKONEPLWBC-UHFFFAOYSA-N 0.000 description 3
- FLTJDUOFAQWHDF-UHFFFAOYSA-N CCCCC(C)(C)C Chemical compound CCCCC(C)(C)C FLTJDUOFAQWHDF-UHFFFAOYSA-N 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 3
- 230000001588 bifunctional effect Effects 0.000 description 3
- 238000012742 biochemical analysis Methods 0.000 description 3
- 229960003230 cetrorelix Drugs 0.000 description 3
- 108700008462 cetrorelix Proteins 0.000 description 3
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 3
- 229960004671 enzalutamide Drugs 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229950010079 lumretuzumab Drugs 0.000 description 3
- 230000005291 magnetic effect Effects 0.000 description 3
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 229950008835 neratinib Drugs 0.000 description 3
- JWNPDZNEKVCWMY-VQHVLOKHSA-N neratinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 JWNPDZNEKVCWMY-VQHVLOKHSA-N 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229960002087 pertuzumab Drugs 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 150000003839 salts Chemical group 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- 229960000575 trastuzumab Drugs 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- UQWNNUPJBDWRHC-UWVGGRQHSA-N (3s,4s)-4-amino-5-cyclohexyl-3-hydroxypentanoic acid Chemical compound OC(=O)C[C@H](O)[C@@H](N)CC1CCCCC1 UQWNNUPJBDWRHC-UWVGGRQHSA-N 0.000 description 2
- PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 description 2
- PBLZLIFKVPJDCO-UHFFFAOYSA-N 12-aminododecanoic acid Chemical compound NCCCCCCCCCCCC(O)=O PBLZLIFKVPJDCO-UHFFFAOYSA-N 0.000 description 2
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 2
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 2
- FBTSQILOGYXGMD-LURJTMIESA-N 3-nitro-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C([N+]([O-])=O)=C1 FBTSQILOGYXGMD-LURJTMIESA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- DFVFTMTWCUHJBL-UHFFFAOYSA-N 4-azaniumyl-3-hydroxy-6-methylheptanoate Chemical compound CC(C)CC(N)C(O)CC(O)=O DFVFTMTWCUHJBL-UHFFFAOYSA-N 0.000 description 2
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 2
- JJMDCOVWQOJGCB-UHFFFAOYSA-N 5-aminopentanoic acid Chemical compound [NH3+]CCCCC([O-])=O JJMDCOVWQOJGCB-UHFFFAOYSA-N 0.000 description 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 2
- 229940123407 Androgen receptor antagonist Drugs 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- BFSQOHINAXSXTP-UHFFFAOYSA-N CCCCCCC(C)(C)C(C)(C)C Chemical compound CCCCCCC(C)(C)C(C)(C)C BFSQOHINAXSXTP-UHFFFAOYSA-N 0.000 description 2
- QDKSGHXRHXVMPF-UHFFFAOYSA-N CCCCCCCCCC(C)(C)C Chemical compound CCCCCCCCCC(C)(C)C QDKSGHXRHXVMPF-UHFFFAOYSA-N 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 2
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 2
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102100024908 Ribosomal protein S6 kinase beta-1 Human genes 0.000 description 2
- 101710108924 Ribosomal protein S6 kinase beta-1 Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 150000004703 alkoxides Chemical class 0.000 description 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000003862 amino acid derivatives Chemical class 0.000 description 2
- 239000003936 androgen receptor antagonist Substances 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 125000001495 ethyl group Chemical class [H]C([H])([H])C([H])([H])* 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000012632 fluorescent imaging Methods 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 229960004657 indocyanine green Drugs 0.000 description 2
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229910052987 metal hydride Inorganic materials 0.000 description 2
- 150000004681 metal hydrides Chemical class 0.000 description 2
- 125000002496 methyl group Chemical class [H]C([H])([H])* 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 2
- 238000009206 nuclear medicine Methods 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
- 229960002340 pentostatin Drugs 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000009258 post-therapy Methods 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000005258 radioactive decay Effects 0.000 description 2
- 108010054624 red fluorescent protein Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Inorganic materials [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 230000001173 tumoral effect Effects 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 231100000747 viability assay Toxicity 0.000 description 2
- 238000003026 viability measurement method Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- BQWBEDSJTMWJAE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[(2-iodoacetyl)amino]benzoate Chemical compound C1=CC(NC(=O)CI)=CC=C1C(=O)ON1C(=O)CCC1=O BQWBEDSJTMWJAE-UHFFFAOYSA-N 0.000 description 1
- GKSPIZSKQWTXQG-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[1-(pyridin-2-yldisulfanyl)ethyl]benzoate Chemical compound C=1C=C(C(=O)ON2C(CCC2=O)=O)C=CC=1C(C)SSC1=CC=CC=N1 GKSPIZSKQWTXQG-UHFFFAOYSA-N 0.000 description 1
- PMJWDPGOWBRILU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCC(C=C1)=CC=C1N1C(=O)C=CC1=O PMJWDPGOWBRILU-UHFFFAOYSA-N 0.000 description 1
- QYEAAMBIUQLHFQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(pyridin-2-yldisulfanyl)propanoylamino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCSSC1=CC=CC=N1 QYEAAMBIUQLHFQ-UHFFFAOYSA-N 0.000 description 1
- FQRURPFZTFUXEZ-MRVPVSSYSA-N (2s)-2,3,3,3-tetrafluoro-2-(n-fluoroanilino)propanoic acid Chemical compound OC(=O)[C@](F)(C(F)(F)F)N(F)C1=CC=CC=C1 FQRURPFZTFUXEZ-MRVPVSSYSA-N 0.000 description 1
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 description 1
- RWLSBXBFZHDHHX-VIFPVBQESA-N (2s)-2-(naphthalen-2-ylamino)propanoic acid Chemical compound C1=CC=CC2=CC(N[C@@H](C)C(O)=O)=CC=C21 RWLSBXBFZHDHHX-VIFPVBQESA-N 0.000 description 1
- NRCSJHVDTAAISV-QMMMGPOBSA-N (2s)-2-amino-3-(3,4-dichlorophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(Cl)C(Cl)=C1 NRCSJHVDTAAISV-QMMMGPOBSA-N 0.000 description 1
- WAMWSIDTKSNDCU-ZETCQYMHSA-N (2s)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@@H](N)C1CCCCC1 WAMWSIDTKSNDCU-ZETCQYMHSA-N 0.000 description 1
- GTVVZTAFGPQSPC-QMMMGPOBSA-N (2s)-2-azaniumyl-3-(4-nitrophenyl)propanoate Chemical compound OC(=O)[C@@H](N)CC1=CC=C([N+]([O-])=O)C=C1 GTVVZTAFGPQSPC-QMMMGPOBSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- OMJKFYKNWZZKTK-POHAHGRESA-N (5z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 1
- NQRKYASMKDDGHT-UHFFFAOYSA-N (aminooxy)acetic acid Chemical compound NOCC(O)=O NQRKYASMKDDGHT-UHFFFAOYSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- NYPYHUZRZVSYKL-UHFFFAOYSA-N -3,5-Diiodotyrosine Natural products OC(=O)C(N)CC1=CC(I)=C(O)C(I)=C1 NYPYHUZRZVSYKL-UHFFFAOYSA-N 0.000 description 1
- BWKMGYQJPOAASG-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CNC(C(=O)O)CC2=C1 BWKMGYQJPOAASG-UHFFFAOYSA-N 0.000 description 1
- DIYPCWKHSODVAP-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 DIYPCWKHSODVAP-UHFFFAOYSA-N 0.000 description 1
- CULQNACJHGHAER-UHFFFAOYSA-N 1-[4-[(2-iodoacetyl)amino]benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=C(NC(=O)CI)C=C1 CULQNACJHGHAER-UHFFFAOYSA-N 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- GUOSQNAUYHMCRU-UHFFFAOYSA-N 11-Aminoundecanoic acid Chemical compound NCCCCCCCCCCC(O)=O GUOSQNAUYHMCRU-UHFFFAOYSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- LFHLEABTNIQIQO-UHFFFAOYSA-N 1H-isoindole Chemical compound C1=CC=C2CN=CC2=C1 LFHLEABTNIQIQO-UHFFFAOYSA-N 0.000 description 1
- ASNTZYQMIUCEBV-UHFFFAOYSA-N 2,5-dioxo-1-[6-[3-(pyridin-2-yldisulfanyl)propanoylamino]hexanoyloxy]pyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCNC(=O)CCSSC1=CC=CC=N1 ASNTZYQMIUCEBV-UHFFFAOYSA-N 0.000 description 1
- QZWBOYMQPQVGPM-UHFFFAOYSA-N 2-(1h-indol-2-yl)guanidine Chemical compound C1=CC=C2NC(NC(=N)N)=CC2=C1 QZWBOYMQPQVGPM-UHFFFAOYSA-N 0.000 description 1
- TXHAHOVNFDVCCC-UHFFFAOYSA-N 2-(tert-butylazaniumyl)acetate Chemical compound CC(C)(C)NCC(O)=O TXHAHOVNFDVCCC-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- VHPXSBIFWDAFMB-UHFFFAOYSA-N 2-amino-Delta(2)-thiazoline-4-carboxylic acid Chemical compound NC1=[NH+]C(C([O-])=O)CS1 VHPXSBIFWDAFMB-UHFFFAOYSA-N 0.000 description 1
- CDULPPOISZOUTK-UHFFFAOYSA-N 2-azaniumyl-3,4-dihydro-1h-naphthalene-2-carboxylate Chemical compound C1=CC=C2CC(N)(C(O)=O)CCC2=C1 CDULPPOISZOUTK-UHFFFAOYSA-N 0.000 description 1
- DGYHPLMPMRKMPD-UHFFFAOYSA-N 2-azaniumylpent-4-ynoate Chemical compound OC(=O)C(N)CC#C DGYHPLMPMRKMPD-UHFFFAOYSA-N 0.000 description 1
- ZFFBIQMNKOJDJE-UHFFFAOYSA-N 2-bromo-1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(Br)C(=O)C1=CC=CC=C1 ZFFBIQMNKOJDJE-UHFFFAOYSA-N 0.000 description 1
- NYCRCTMDYITATC-UHFFFAOYSA-N 2-fluorophenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1F NYCRCTMDYITATC-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- NYPYHUZRZVSYKL-ZETCQYMHSA-N 3,5-diiodo-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC(I)=C(O)C(I)=C1 NYPYHUZRZVSYKL-ZETCQYMHSA-N 0.000 description 1
- AJHPGXZOIAYYDW-UHFFFAOYSA-N 3-(2-cyanophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)CC1=CC=CC=C1C#N AJHPGXZOIAYYDW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ACWBBAGYTKWBCD-ZETCQYMHSA-N 3-chloro-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(Cl)=C1 ACWBBAGYTKWBCD-ZETCQYMHSA-N 0.000 description 1
- UQTZMGFTRHFAAM-ZETCQYMHSA-N 3-iodo-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(I)=C1 UQTZMGFTRHFAAM-ZETCQYMHSA-N 0.000 description 1
- MQHLULPKDLJASZ-QMMMGPOBSA-N 3-methyl-L-tyrosine zwitterion Chemical compound CC1=CC(C[C@H](N)C(O)=O)=CC=C1O MQHLULPKDLJASZ-QMMMGPOBSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- CMUHFUGDYMFHEI-QMMMGPOBSA-N 4-amino-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N)C=C1 CMUHFUGDYMFHEI-QMMMGPOBSA-N 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- NIGWMJHCCYYCSF-QMMMGPOBSA-N 4-chloro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-QMMMGPOBSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- PZNQZSRPDOEBMS-QMMMGPOBSA-N 4-iodo-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(I)C=C1 PZNQZSRPDOEBMS-QMMMGPOBSA-N 0.000 description 1
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 1
- OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 1
- AWQSAIIDOMEEOD-UHFFFAOYSA-N 5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone Chemical compound CC(=O)CCC1CC(=O)OC1(C)C AWQSAIIDOMEEOD-UHFFFAOYSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- IDLISIVVYLGCKO-UHFFFAOYSA-N 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein Chemical compound O1C(=O)C2=CC=C(C(O)=O)C=C2C21C1=CC(OC)=C(O)C(Cl)=C1OC1=C2C=C(OC)C(O)=C1Cl IDLISIVVYLGCKO-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- DOCINCLJNAXZQF-LBPRGKRZSA-N 6-fluoro-3-phenyl-2-[(1s)-1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=NC2=CC=C(F)C=C2C(=O)N1C1=CC=CC=C1 DOCINCLJNAXZQF-LBPRGKRZSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 101800001718 Amyloid-beta protein Proteins 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- CRSOQBOWXPBRES-UHFFFAOYSA-N CC(C)(C)C Chemical compound CC(C)(C)C CRSOQBOWXPBRES-UHFFFAOYSA-N 0.000 description 1
- SPZUILOYMONKLS-UHFFFAOYSA-N CC(C)(C)C(=S)NC1=CC=C(CC2CN(CC(=O)O)CCN(CC(=O)O)CCN2CC(=O)O)C=C1 Chemical compound CC(C)(C)C(=S)NC1=CC=C(CC2CN(CC(=O)O)CCN(CC(=O)O)CCN2CC(=O)O)C=C1 SPZUILOYMONKLS-UHFFFAOYSA-N 0.000 description 1
- GUMULFRCHLJNDY-UHFFFAOYSA-N CC(C)(C)CC(C)(C)C Chemical compound CC(C)(C)CC(C)(C)C GUMULFRCHLJNDY-UHFFFAOYSA-N 0.000 description 1
- 101001059929 Caenorhabditis elegans Forkhead box protein O Proteins 0.000 description 1
- 102100033620 Calponin-1 Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 229910052692 Dysprosium Inorganic materials 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 229910052691 Erbium Inorganic materials 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010081348 HRT1 protein Hairy Proteins 0.000 description 1
- 102100039990 Hairy/enhancer-of-split related with YRPW motif protein 2 Human genes 0.000 description 1
- 229910052689 Holmium Inorganic materials 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- AMDBBAQNWSUWGN-UHFFFAOYSA-N Ioversol Chemical compound OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I AMDBBAQNWSUWGN-UHFFFAOYSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- LOOZZTFGSTZNRX-VIFPVBQESA-N L-Homotyrosine Chemical compound OC(=O)[C@@H](N)CCC1=CC=C(O)C=C1 LOOZZTFGSTZNRX-VIFPVBQESA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
- DZLNHFMRPBPULJ-VKHMYHEASA-N L-thioproline Chemical compound OC(=O)[C@@H]1CSCN1 DZLNHFMRPBPULJ-VKHMYHEASA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
- 244000137850 Marrubium vulgare Species 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- NZXKDOXHBHYTKP-UHFFFAOYSA-N Metohexital Chemical compound CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O NZXKDOXHBHYTKP-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical compound [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- AWZJFZMWSUBJAJ-UHFFFAOYSA-N OG-514 dye Chemical compound OC(=O)CSC1=C(F)C(F)=C(C(O)=O)C(C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)=C1F AWZJFZMWSUBJAJ-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
- PEMUHKUIQHFMTH-UHFFFAOYSA-N P-Bromo-DL-phenylalanine Chemical compound OC(=O)C(N)CC1=CC=C(Br)C=C1 PEMUHKUIQHFMTH-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 229910052771 Terbium Inorganic materials 0.000 description 1
- IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 1
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229910052769 Ytterbium Inorganic materials 0.000 description 1
- ZTOJFFHGPLIVKC-CLFAGFIQSA-N abts Chemical compound S/1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-CLFAGFIQSA-N 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229960001391 alfentanil Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-UHFFFAOYSA-N alpha-phenylglycine Chemical compound OC(=O)C(N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- CZPLANDPABRVHX-UHFFFAOYSA-N cascade blue Chemical compound C=1C2=CC=CC=C2C(NCC)=CC=1C(C=1C=CC(=CC=1)N(CC)CC)=C1C=CC(=[N+](CC)CC)C=C1 CZPLANDPABRVHX-UHFFFAOYSA-N 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- BFGKITSFLPAWGI-UHFFFAOYSA-N chromium(3+) Chemical compound [Cr+3] BFGKITSFLPAWGI-UHFFFAOYSA-N 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 230000003021 clonogenic effect Effects 0.000 description 1
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- DPYMFVXJLLWWEU-UHFFFAOYSA-N desflurane Chemical compound FC(F)OC(F)C(F)(F)F DPYMFVXJLLWWEU-UHFFFAOYSA-N 0.000 description 1
- 229960003537 desflurane Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical class CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 229960005423 diatrizoate Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- JPGQOUSTVILISH-UHFFFAOYSA-N enflurane Chemical compound FC(F)OC(F)(F)C(F)Cl JPGQOUSTVILISH-UHFFFAOYSA-N 0.000 description 1
- 229960000305 enflurane Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960001690 etomidate Drugs 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 229940005494 general anesthetics Drugs 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 1
- CBMIPXHVOVTTTL-UHFFFAOYSA-N gold(3+) Chemical compound [Au+3] CBMIPXHVOVTTTL-UHFFFAOYSA-N 0.000 description 1
- 230000009629 growth pathway Effects 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- QNRXNRGSOJZINA-UHFFFAOYSA-N indoline-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)CC2=C1 QNRXNRGSOJZINA-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 229960004359 iodixanol Drugs 0.000 description 1
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 1
- 229960001025 iohexol Drugs 0.000 description 1
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 1
- 229960004647 iopamidol Drugs 0.000 description 1
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 description 1
- 229960002603 iopromide Drugs 0.000 description 1
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 description 1
- 229960004537 ioversol Drugs 0.000 description 1
- 229940029407 ioxaglate Drugs 0.000 description 1
- TYYBFXNZMFNZJT-UHFFFAOYSA-N ioxaglic acid Chemical compound CNC(=O)C1=C(I)C(N(C)C(C)=O)=C(I)C(C(=O)NCC(=O)NC=2C(=C(C(=O)NCCO)C(I)=C(C(O)=O)C=2I)I)=C1I TYYBFXNZMFNZJT-UHFFFAOYSA-N 0.000 description 1
- 229960002611 ioxilan Drugs 0.000 description 1
- UUMLTINZBQPNGF-UHFFFAOYSA-N ioxilan Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCCO)=C(I)C(C(=O)NCC(O)CO)=C1I UUMLTINZBQPNGF-UHFFFAOYSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- CZMAIROVPAYCMU-UHFFFAOYSA-N lanthanum(3+) Chemical compound [La+3] CZMAIROVPAYCMU-UHFFFAOYSA-N 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 229960003406 levorphanol Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 238000006263 metalation reaction Methods 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960002683 methohexital Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 1
- 229960002455 methoxyflurane Drugs 0.000 description 1
- 229960004712 metrizoic acid Drugs 0.000 description 1
- GGGDNPWHMNJRFN-UHFFFAOYSA-N metrizoic acid Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I GGGDNPWHMNJRFN-UHFFFAOYSA-N 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000011201 multiple comparisons test Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
- 229960000805 nalbuphine Drugs 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 229960001730 nitrous oxide Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- CQYBNXGHMBNGCG-RNJXMRFFSA-N octahydroindole-2-carboxylic acid Chemical compound C1CCC[C@H]2N[C@H](C(=O)O)C[C@@H]21 CQYBNXGHMBNGCG-RNJXMRFFSA-N 0.000 description 1
- 230000006712 oncogenic signaling pathway Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- 229960005118 oxymorphone Drugs 0.000 description 1
- VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 description 1
- 229960003394 remifentanil Drugs 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960001549 ropivacaine Drugs 0.000 description 1
- DOSGOCSVHPUUIA-UHFFFAOYSA-N samarium(3+) Chemical compound [Sm+3] DOSGOCSVHPUUIA-UHFFFAOYSA-N 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- DFEYYRMXOJXZRJ-UHFFFAOYSA-N sevoflurane Chemical compound FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 description 1
- 229960002078 sevoflurane Drugs 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
- RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- DFVFTMTWCUHJBL-BQBZGAKWSA-N statine Chemical compound CC(C)C[C@H](N)[C@@H](O)CC(O)=O DFVFTMTWCUHJBL-BQBZGAKWSA-N 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- XLOMZPUITCYLMJ-UHFFFAOYSA-N thiamylal Chemical compound CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O XLOMZPUITCYLMJ-UHFFFAOYSA-N 0.000 description 1
- 229960001166 thiamylal Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000006177 thiolation reaction Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229960003279 thiopental Drugs 0.000 description 1
- DZLNHFMRPBPULJ-UHFFFAOYSA-N thioproline Chemical compound OC(=O)C1CSCN1 DZLNHFMRPBPULJ-UHFFFAOYSA-N 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- PLHJCIYEEKOWNM-HHHXNRCGSA-N tipifarnib Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 description 1
- 229950009158 tipifarnib Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
- 229950001353 tretamine Drugs 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- HHJUWIANJFBDHT-KOTLKJBCSA-N vindesine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(N)=O)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 HHJUWIANJFBDHT-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Definitions
- This invention relates to compositions useful for imaging techniques, and more particularly to compounds that are useful for imaging HER3 using medical imaging, including positron emission tomography.
- the receptor tyrosine kinase HER3 (ERBB3) is upregulated in response to targeted therapies in multiple cancers, including lung, breast and prostate cancers.
- ERBB3 receptor tyrosine kinase HER3
- levels of HER3 expression are highly dynamic, making quantification by tissue sampling techniques such as biopsy potentially inaccurate.
- PET imaging which permits global and serial imaging, may present a more robust method for HER3 quantification, improving HER3 diagnosis, facilitating improved clinical trials assessing HER3 expression, and, in the long term, providing accurate diagnosis of HER3 status to help diagnosis targeted therapy resistance.
- A comprises an imaging agent
- B is a linking group or a covalent bond
- C is a polypeptide comprising from about 9 to about 75 amino acids, wherein the polypeptide comprises an amino acid sequence having at least 90% sequence identity to:
- X 2 is selected from the group consisting of L, L*, I, I*, P, P*, V, V*, G, and G*;
- X 3 is selected from the group consisting of P, P*, L, L*, I, I*, V, V*, G, and G*;
- X 4 is selected from the group consisting of T, T*, S, S*, C, C*, M, and M*;
- X 5 is selected from the group consisting of any L-amino acid, any D-amino acid, and any non-natural amino acid;
- X 6 is selected from the group consisting of any L-amino acid, any D-amino acid, and any non-natural amino acid;
- X 7 is selected from the group consisting of R, R*, H, H*, K, K*, N, N*, Q, and Q*, and
- X 8 is selected from the group consisting of S, S*, T, T*, C, C*, M, and M*,
- L* is a non-natural derivative of L
- I* is a non-natural derivative of I
- P* is a non-natural derivative of P
- V* is a non-natural derivative of V
- G* is a non-natural derivative of G
- T* is a non-natural derivative of T
- S* is a non-natural derivative of S
- C* is a non-natural derivative of C
- M* is a non-natural derivative of M
- R* is a non-natural derivative of R
- H* is a non-natural derivative of H
- K* is a non-natural derivative of K
- N* is a non-natural derivative of N
- Q* is a non-natural derivative of Q.
- A comprises one or more imaging agents selected from the group consisting of a paramagnetic ion, an x-ray imaging agent, a fluorophore, and a radioisotope. In some embodiments, A comprises a radioisotope. In some embodiments, the radioisotope is suitable for PET imaging.
- the radioisotope is selected from the group consisting of 3 H, 11 C, 14 C, 18 F, 32 P, 35 S, 36 Cl, 51 Cr, 52 Fe, 57 Co, 58 Co, 59 Fe, 64 Cu, 67 Cu, 67 Ga, 68 Ga, 75 Se, 76 Br, 77 Br, 89 Zr, 90 , 99m Tc, 111 In, 123 I, 124 I, 125 I, 131 I, 152 Eu, 153 Sm, 166 Ho, 177 Lu, 186 Re, 188 Re, 201 Tl, 203 Pb, 210 At, 211 At, 212 Bi, 213 Bi, and 225 Ac.
- the radioisotope selected from the group consisting of 3 H, 11 C, 14 C 18 F, 35 S, 52 Fe, 58 Co, 64 Cu, 68 Ga, 76 Br, 77 Br, 89 Zr, 111 In, 123 I, 124 I, 125 I, 131 I, 186 Re, 188 Re, and 201 Tl.
- A comprises 68 Ga.
- A further comprises a chelating agent.
- the chelating agent is selected from the group consisting of 1,4,7-triazacyclononanetriacetic acid (NOTA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 1,4,7-triazacyclononane-1-glutaric acid-4,7-diacetic acid (NODAGA), ethylene diamine tetra-acetic acid (EDTA), diethylene triaminepentaacetic acid (DTPA), cyclohexyl-1,2-diaminetetraacetic acid (CDTA), ethyleneglycol-O,O′-bis(2-aminoethyl)-N,N,N′,N′-tetraacetic acid (EGTA), N,N-bis(hydroxybenzyl)-ethylenediamine-N,N′-diacetic acid (HBED), triethylene tetramine hexa
- the chelating agent is selected from the group consisting of 1,4,7-triazacyclononanetriacetic acid (NOTA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 1,4,7-triazacyclononane-1-glutaric acid-4,7-diacetic acid (NODAGA), and 2,2′,2′′-(2-(4-isothiocyanatobenzyl)-1,4,7-triazonane-1,4,7-triyl)triacetic acid (NOTA-NCS).
- NOTA 1,4,7-triazacyclononanetriacetic acid
- DOTA 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
- NODAGA 1,4,7-triazacyclononane-1-glutaric acid-4,7-diacetic acid
- NCS 2,2′,2′′-(2-(4-isothi
- the chelating agent is 1,4,7-triazacyclononanetriacetic acid (NOTA) or 2,2′,2′′-(2-(4-isothiocyanatobenzyl)-1,4,7-triazonane-1,4,7-triyl)triacetic acid (NOTA-NCS).
- B is a linking group.
- B is a linking group comprising one or more C 1-30 alkyleneoxy groups, one or more independently selected amino acids, or any combination thereof. In some embodiments, B is a linking group comprising from about 1 to about 10 independently selected amino acids. In some embodiments, B is a linking group comprising a sequence having at least 90% sequence identity to:
- v refers to the bond between B and C
- X 9 is selected from the group consisting of beta A, 6-aminohexanoic acid, 8-aminooctanoic acid, and 2-(2-(2-aminoethoxy)ethoxy)acetic acid;
- X 10 is selected from the group consisting of G, G*, A, A*, S, S*, P, P*, W, W*, Y, Y*, H, H*, T, T*, M, M*, N, N*, Q, and Q*;
- X 1 is selected from the group consisting of G, G*, A, A*, S, S*, P, P*, W, W*, Y, Y*, H, H*, T, T*, M, M*, N, N*, Q, and Q*;
- X 12 is selected from the group consisting of G, G*, A, A*, S, S*, P, P*, W, W*, Y, Y*, H, H*, T, T*, M, M*, N, N*, Q, and Q*;
- G* is a non-natural derivative of G
- A* is a non-natural derivative of A
- S* is a non-natural derivative of S
- P* is a non-natural derivative of P
- W* is a non-natural derivative of W
- Y* is a non-natural derivative of Y
- H* is a non-natural derivative of H
- T* is a non-natural derivative of T
- M* is a non-natural derivative of M
- N* is a non-natural derivative of N
- Q* is a non-natural derivative of Q.
- B is a linking group which is:
- C is a polypeptide comprising from about 15 to about 25 amino acids, wherein the polypeptide comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 12.
- X 2 is L or L*.
- X 3 is P or P*.
- X 4 is T or T*.
- X 5 is K or K*.
- X 6 is F or F*.
- X 7 is R or R*.
- X 8 is S or S*.
- composition of Formula I is a composition of Formula Ia:
- composition of Formula I is a composition of Formula Ib:
- A′ is a radioisotope
- composition of Formula I is a composition of Formula Ic:
- composition of Formula I is:
- the present application further provides a composition of Formula II: B—C
- B comprises from about 1 to about 10 amino acids
- C is a polypeptide comprising from about 9 to about 75 amino acids, wherein the polypeptide comprises an amino acid sequence having at least 90% sequence identity to:
- X 2 is selected from the group consisting of L, L*, I, I*, P, P*, V, V*, G, and G*;
- X 3 is selected from the group consisting of P, P*, L, L*, I, I*, V, V*, G, and G*;
- X 4 is selected from the group consisting of T, T*, S, S*, C, C*, M, and M*;
- X 5 is selected from the group consisting of any L-amino acid, any D-amino acid, and any non-natural amino acid;
- X 6 is selected from the group consisting of any L-amino acid, any D-amino acid, and any non-natural amino acid;
- X 7 is selected from the group consisting of R, R*, H, H*, K, K*, N, N*, Q, and Q*, and
- X 8 is selected from the group consisting of S, S*, T, T*, C, C*, M, and M*,
- L* is a non-natural derivative of L
- I* is a non-natural derivative of I
- P* is a non-natural derivative of P
- V* is a non-natural derivative of V
- G* is a non-natural derivative of G
- T* is a non-natural derivative of T
- S* is a non-natural derivative of S
- C* is a non-natural derivative of C
- M* is a non-natural derivative of M
- R* is a non-natural derivative of R
- H* is a non-natural derivative of H
- K* is a non-natural derivative of K
- N* is a non-natural derivative of N
- Q* is a non-natural derivative of Q.
- B comprises a sequence having at least 90% sequence identity to:
- X 9 is selected from the group consisting of beta A, 6-aminohexanoic acid, 8-aminooctanoic acid, and 2-(2-(2-aminoethoxy)ethoxy)acetic acid;
- X 10 is selected from the group consisting of G, G*, A, A*, S, S*, P, P*, W, W*, Y, Y*, H, H*, T, T*, M, M*, N, N*, Q, and Q*;
- X 11 is selected from the group consisting of G, G*, A, A*, S, S*, P, P*, W, W*, Y, Y*, H, H*, T, T*, M, M*, N, N*, Q, and Q*; and
- X 12 is selected from the group consisting of G, G*, A, A*, S, S*, P, P*, W, W*, Y, Y*, H, H*, T, T*, M, M*, N, N*, Q, and Q*;
- G* is a non-natural derivative of G
- A* is a non-natural derivative of A
- S* is a non-natural derivative of S
- P* is a non-natural derivative of P
- W* is a non-natural derivative of W
- Y* is a non-natural derivative of Y
- H* is a non-natural derivative of H
- T* is a non-natural derivative of T
- M* is a non-natural derivative of M
- N* is a non-natural derivative of N
- Q* is a non-natural derivative of Q.
- B is:
- C is a polypeptide comprising from about 15 to about 25 amino acids, wherein the polypeptide comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1.
- X 2 is L or L*.
- X 3 is P or P*.
- X 4 is T or T*.
- X 5 is K or K*.
- X 6 is F or F*.
- X 7 is R or R*.
- X 8 is S or S*.
- composition of Formula II is a composition of Formula IIa:
- composition of Formula II is
- C is a polypeptide that binds HER3.
- the present application further provides a pharmaceutical composition
- a pharmaceutical composition comprising a composition provided herein, and a pharmaceutically acceptable carrier.
- the present application further provides a method of imaging cancer in a subject, the method comprising:
- compositions provided herein e.g., a composition of Formula I
- the present application further provides a method of treating a cancer in a subject, the method comprising:
- compositions provided herein e.g., a composition of Formula I
- the present application further provides a method of monitoring treatment of a cancer in a subject, the method comprising:
- compositions provided herein e.g., a composition of Formula I
- the methods provided herein further comprise administering an additional effective amount of the composition to the subject after step iii). In some embodiments, the methods provided herein further comprise imaging the subject with a suitable imaging technique after step iii).
- the therapeutic agent is a chemotherapeutic agent. In some embodiments, the therapeutic agent is a HER3 inhibitor. In some embodiments, the therapeutic agent is selected from the group consisting of patritumab, MM-121, U3-1402, GSK2849330, neratinib, lumretuzumab, U3-1287, Sym013, AV-203, trastuzumab, pertuzumab, cetrorelix, enzalutamide, and erlotinib.
- the cancer is a solid tumor.
- the cancer is selected from the group consisting of breast cancer, lung cancer, prostate cancer, gastric cancer, head and neck cancer, and ovarian cancer.
- the prostate cancer is castration resistant prostate cancer.
- the imaging technique is selected from the group consisting of magnetic resonance (MR) imaging, positron emission tomography (PET) imaging, fluorescent imaging, single photon emission computed tomography (SPECT), luminescent imaging, or any combination thereof.
- MR magnetic resonance
- PET positron emission tomography
- SPECT single photon emission computed tomography
- luminescent imaging or any combination thereof.
- the imaging technique is positron emission tomography (PET) imaging.
- FIG. 1A shows a heat map of standardized phage supernatant binding to HER3 and BSA as a control. White indicates high binding and black indicates low binding.
- FIG. 1B shows normalized binding of the 5 highest phage from supernatant phage ELISA, bars represent the mean of 6 replicates ⁇ SEM.
- FIG. 1C shows sequences of phages with high binding (1, 5, 17, 19, 26) and low binding (7, 22, 27) to HER3. ** P ⁇ 0.01.
- FIG. 2A shows peptide ELISA with increasing concentrations of HER3P1 demonstrates saturable binding and an affinity of 270 ⁇ 151 nM.
- Triangles represent the mean of 6 replicates ⁇ SEM.
- FIG. 2B shows measured HER3P1 absorbance against two similar receptor tyrosine kinases and BSA, demonstrating approximately 4-fold selectivity over closely related proteins. Bars represent the mean of 6 replicates ⁇ SEM. * * P ⁇ 0.01.
- FIG. 3A shows quantitative measurement of HER3-1 binding to moderate (MDA MB-453) and low (HCC-1954) HER3 expressing cells reveals significant differentiation by HER3P1 between cell types, in addition to significantly higher binding to a moderate HER3 cell line than a control peptide.
- FIG. 3B shows fluorescent microscopy visualizes peptide binding to MDA-MB-453 cells, with little binding to HCC-1954 cells. * P ⁇ 0.05.
- FIG. 3C shows results of a 68 Ga-HER3P1 (i.e., 68 Ga—(NOTA-NCS)-HER3P1) competitive binding assay (P ⁇ 0.05).
- FIG. 4A shows sagittal and axial maximum intensity projections of the radiolabeled peptide ( 68 Ga—(NOTA-NCS)-HER3P1) in high HER3 expressing 22RV1 and low HER3 expressing HCC-1954 tumors. Peptide uptake is visualized in tumor and kidneys, which are the main route of clearance.
- FIG. 4B shows western blot analysis of HER3 and ⁇ -actin for tumors excised from mice following PET imaging.
- FIG. 4C shows quantification of HER3: ⁇ -actin ratio for 22RV1 and HCC-1954 tumors. Bars represent the mean of 4 replicates ⁇ SEM.
- FIG. 4D shows linear regression with 95% confidence intervals for each tumor comparing PET TBR to ex vivo HER3: ⁇ -actin ratio. Linear significance was determined by a Pearson's correlation.** P ⁇ 0.01, *** p ⁇ 0.0001.
- FIG. 5A shows biodistribution of 68 Ga—(NOTA-NCS)-HER3P1 in depicted organs as the mean injected dose per gram of tissue (% ID/g) of four 22RV1 tumor bearing mice ⁇ SD.
- FIG. 5B shows tumor to organ ratios calculated by biodistribution values from FIG. 5A demonstrating specific accumulation in murine sites of non-tumor tissue HER3 expression.
- FIG. 5C shows linear regression of TBR from both biodistribution versus PET imaging. Significance of linearity determined by Pearson's correlation. * P ⁇ 0.05, *** P ⁇ 0.001.
- FIG. 6 shows mean phage binding normalized to parent (HER3P1) peptide.
- M1 corresponds to mutant in position 1 following the cysteine, which is position 2 of the binding sequence.
- Each of the subsequent phages (M2, M3, etc.) follow this naming convention. Bars represent the mean of 4 replicates with error bars denoting standard error measurements.
- FIG. 7 shows the measured SUV mean of mice bearing MDA-MB-453 HER2+ lapatinib resistant tumors were imaged pre-(circles) and post-therapy (squares) each point represents a matched pair of images from a single mouse imaged at day 0 pre-therapy and 2 days post therapy initiation. Bars represent mean and standard error measurement.
- FIG. 8 shows representative PET/MR images of a single mouse (mouse 1) pre-lapatinib (left image) and 2 days post-lapatinib therapy (right image). Tumors are circled and labeled with a white (T). Kidneys, which are the main route of peptide clearance, are labeled with a black K.
- Molecular targeted cancer therapy while providing benefits for a number of indications, has so far failed to produce durable responses in a majority of patients (see e.g., Herbst et al, Journal of Clinical Oncology, 2005, 23:5892-5899). While no single mechanism is entirely responsible for targeted therapy resistance, a recurring theme is the upregulation of feedback loops that circumvent blockade of an oncogenic signaling pathway. Feedback loop signaling can be accomplished through alternative activation of a homologous pathway or through over-expression of a secondary oncogenic protein.
- HER3 human epidermal growth factor receptor 3
- HER3 human epidermal growth factor receptor 3
- HER3 is a member of the epidermal growth factor (EGF) family of receptors that includes EGFR, HER2/ErbB2/neu, HER3/ErbB3 and HER4/ErbB4.
- the EGFR family canonically function through ligand binding followed by dimerization, phosphorylation and downstream signaling through the MAPK and PI3K/AKT pathways (see e.g., Yarden, Y. Nature Reviews Molecular Cell Biology, 2001, 2: 127; Schlessinger, J. Cell, 2000, 103:211-225; and Ferguson et al, EMBO J. 2000, 19: 4632-4643).
- HER3 has been less explored historically due to its mutated kinase domain, concurrent discoveries that its intracellular domain can in fact signal through transphosphorylation and that it is over-expressed in patients with resistance to a number of targeted therapies have brought it to the forefront of targeted therapy development (see e.g., Shi et al, Proceedings of the national Academy of Sciences, 2010, 107: 7692-7697).
- HER3-mediated therapeutic resistance may not be limited to therapies that target EGFR or HER2, as evidence has emerged to link HER3 with castration resistant prostate cancer as well.
- HER3 in targeted therapy resistance has been well documented, and efforts to pharmacologically inhibit its activity are currently being explored.
- Clinical trials examining the efficacy of anti-HER3 antibodies including patritumab (NCT0213401S), MM-121 (NCT00734305), U3-1402 (NCT02980341), and GSK2849330 (NCT0196644S) are ongoing or have been completed recently, with limited success to date.
- One limiting factor for the administration of such agents is identifying patient populations most likely to benefit from the therapy.
- HER3 is particularly challenging to quantify by biopsy, because of its highly heterogeneous temporal and spatial expression.
- PET imaging which provides a global and repeatable methodology to assess target expression, is highly compatible with HER3 expression diagnosis.
- the present application provides a novel HER3 peptide for quantitative PET imaging of HER3 expressing tumors in murine models of multiple cancers.
- the novel HER3 peptide, HER3P1 represents an accurate, pharmacokinetically favorable peptide imaging agent for HER3.
- HER3 represents a critical protein in targeted therapies for a number of cancers and its highly dynamic expression requires an equally dynamic approach to quantification.
- HER3 imaging with HER3P1 may represent a method to quantify HER3 and provide critical cellular feedback analysis.
- A comprises an imaging agent
- B is a linking group or a covalent bond
- C is a polypeptide comprising from about 9 to about 75 amino acids, wherein the polypeptide comprises an amino acid sequence having at least 90% sequence identity to:
- X 2 is selected from the group consisting of L, L*, I, I*, P, P*, V, V*, G, and G*;
- X 3 is selected from the group consisting of P, P*, L, L*, I, I*, V, V*, G, and G*;
- X 4 is selected from the group consisting of T, T*, S, S*, C, C*, M, and M*;
- X 5 is selected from the group consisting of any L-amino acid, any D-amino acid, and any non-natural amino acid;
- X 6 is selected from the group consisting of any L-amino acid, any D-amino acid, and any non-natural amino acid;
- X 7 is selected from the group consisting of R, R*, H, H*, K, K*, N, N*, Q, and Q*, and
- X 8 is selected from the group consisting of S, S*, T, T*, C, C*, M, and M*,
- L* is a non-natural derivative of L
- I* is a non-natural derivative of I
- P* is a non-natural derivative of P
- V* is a non-natural derivative of V
- G* is a non-natural derivative of G
- T* is a non-natural derivative of T
- S* is a non-natural derivative of S
- C* is a non-natural derivative of C
- M* is a non-natural derivative of M
- R* is a non-natural derivative of R
- H* is a non-natural derivative of H
- K* is a non-natural derivative of K
- N* is a non-natural derivative of N
- Q* is a non-natural derivative of Q.
- A comprises an imaging agent selected from the group consisting of a paramagnetic ion, an x-ray imaging agent, a fluorophore, and a radioisotope.
- A comprises a paramagnetic ion.
- the paramagnetic ion is selected from the group consisting of chromium (III), manganese (II), iron (III), iron (II), cobalt (II), nickel (II), copper (II), neodymium (III), samarium (III), ytterbium (III), gadolinium (III), vanadium (II), terbium (III), dysprosium (III), holmium (III), and erbium (III).
- A comprises an x-ray imaging agent.
- the x-ray imaging agent is selected from the group consisting of lanthanum (III), gold (III), lead (II), bismuth (III), and iodinated x-ray imaging agents (e.g, diatrizoate, ioxaglate, metrizoate, iopamidol, iohexol, ioxilan, iopromide, iodixanol, and ioversol).
- A comprises a fluorophore.
- the fluorophore is selected from the group consisting of Alexa 350, Alexa 430, AMCA, BODIPY 630/650, BODIPY 650/665, BODIPY-FL, BODPY-R6G, 13BODLPY-TMR, BODLPY-TRX, cascade blue, Cy3, Cy5, 6-FAM, fluorescein isothiocyanate, HEX, 6-JOE, oregon green 488, oregon green 500, oregon green 514, quantum dots, pacific blue, REG, rhodamine green, rhodamine red, renographin, ROX, TAMRA, TET, tetramethylrhodamine, Texas Red, the Alexafluor family, Cy5, Cy5.5, Cy7, indocyanine green (ICG), and fluorescent proteins (e.g., green fluorescent protein (GFP), red fluorescent protein (RFP), and ds
- GFP green fluorescent protein
- A comprises a radioisotope.
- the radioisotope provided herein is useful as an imaging agent in one or more of the methods provided herein.
- the radioisotope is suitable for PET imaging.
- the radioisotope provided herein may also be useful in one or more therapeutic applications, for example, when administered to a subject in a therapeutically effective amount.
- 131 I and 64 Cu may be useful as imaging agents (e.g., as non-toxic and/or non-therapeutic radioisotopes) when administered to the subject at low concentrations (e.g., 5 mCi) and may also be useful as therapeutic agents (i.e., as toxic radioisotopes and/or therapeutic radioisotopes) when administered to the subject at a higher concentration.
- the radioisotope is selected from the group consisting of 3 H, 11 C, 14 C, 18 F, 32 P, 35 S, 36 Cl, 51 Cr, 52 Fe, 57 Co, 58 Co, 59 Fe, 64 Cu, 67 Cu, 67 Ga, 68 Ga, 75 Se, 76 Br, 77 Br, 89 Zr, 90 , 99m Tc, 111 In, 123 I, 124 I, 125 I, 131 I, 152 Eu, 153 Sm, 166 Ho, 177 Lu, 186 Re, 188 Re, 201 Tl, 203 Pb, 210 At, 211 At, 212 Bi, 213 Bi, and 225 Ac.
- the radioisotope is selected from the group consisting of 3 H, 11 C, 14 C 18 F, 35 S, 52 Fe, 58 Co, 64 Cu, 68 Ga, 76 Br, 77 Br, 89 Zr, 111 In, 123 I, 124 I, 125 I, 131 I, 186 Re, 188 Re, and 201 Tl.
- the radioisotope is 68 Ga.
- A further comprises a chelating agent.
- the chelating agent is selected from the group consisting of 1,4,7-triazacyclononanetriacetic acid (NOTA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 1,4,7-triazacyclononane-1-glutaric acid-4,7-diacetic acid (NODAGA), ethylene diamine tetra-acetic acid (EDTA), diethylene triaminepentaacetic acid (DTPA), cyclohexyl-1,2-diaminetetraacetic acid (CDTA), ethyleneglycol-O,O′-bis(2-aminoethyl)-N,N,N′,N′-tetraacetic acid (EGTA), N,N-bis(hydroxybenzyl)-ethylenediamine-N,N′-diacetic acid (HBED), triethylene tetramine hexa
- the chelating agent is selected from the group consisting of 1,4,7-triazacyclononanetriacetic acid (NOTA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 1,4,7-triazacyclononane-1-glutaric acid-4,7-diacetic acid (NODAGA), and 2,2′,2′′-(2-(4-isothiocyanatobenzyl)-1,4,7-triazonane-1,4,7-triyl)triacetic acid (NOTA-NCS).
- NOTA 1,4,7-triazacyclononanetriacetic acid
- DOTA 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
- NODAGA 1,4,7-triazacyclononane-1-glutaric acid-4,7-diacetic acid
- NCS 2,2′,2′′-(2-(4-isothi
- the chelating agent is 1,4,7-triazacyclononanetriacetic acid (NOTA) or 2,2′,2′′-(2-(4-isothiocyanatobenzyl)-1,4,7-triazonane-1,4,7-triyl)triacetic acid (NOTA-NCS).
- NOTA-NCS 2,2′,2′′-(2-(4-isothiocyanatobenzyl)-1,4,7-triazonane-1,4,7-triyl)triacetic acid
- the chelating agent is:
- B is a covalent bond. In some embodiments, B is a linking group.
- B is a linking group comprising one or more C 1-30 alkyleneoxy groups, one or more independently amino acids, or any combination thereof.
- B is a linking group comprising one or more C 1-30 alkyleneoxy groups. In some embodiments, B is a linking group comprising one or more —(OCH 2 CH 2 )— groups. In some embodiments, B is a linking group comprising one or more —(OCH 2 CH 2 ) p — groups, wherein p is an integer from 1 to 15, for example, 1 to 10, 1 to 5, 5 to 15, 5 to 10, or 10 to 15.
- B is a linking group comprising a combination of one or more C 1-30 alkyleneoxy groups and one or more independently selected amino acids.
- B is a linking group comprising one or more independently selected amino acids. In some embodiments, B is a linking group comprising from about 1 to about 20 independently selected amino acids, for example, about 1 to about 15, about 1 to about 10, about 1 to about 5, about 5 to about 20, about 5 to about 15, about 5 to about 10, about 10 to about 20, about 10 to about 15, or about 15 to about 20 independently selected amino acids. In some embodiments, B is a linking group comprising from about 1 to about 10 independently selected amino acids.
- B is a linking group comprising a sequence having at least 90% sequence identity to:
- X 9 is selected from the group consisting of beta A, 6-aminohexanoic acid, 8-aminooctanoic acid, and 2-(2-(2-aminoethoxy)ethoxy)acetic acid;
- X 10 is selected from the group consisting of G, G*, A, A*, S, S*, P, P*, W, W*, Y, Y*, H, H*, T, T*, M, M*, N, N*, Q, and Q*;
- X 11 is selected from the group consisting of G, G*, A, A*, S, S*, P, P*, W, W*, Y, Y*, H, H*, T, T*, M, M*, N, N*, Q, and Q*; and
- X 12 is selected from the group consisting of G, G*, A, A*, S, S*, P, P*, W, W*, Y, Y*, H, H*, T, T*, M, M*, N, N*, Q, and Q*;
- G* is a non-natural derivative of G
- A* is a non-natural derivative of A
- S* is a non-natural derivative of S
- P* is a non-natural derivative of P
- W* is a non-natural derivative of W
- Y* is a non-natural derivative of Y
- H* is a non-natural derivative of H
- T* is a non-natural derivative of T
- M* is a non-natural derivative of M
- N* is a non-natural derivative of N
- Q* is a non-natural derivative of Q.
- X 9 is beta A.
- X 10 is G or G*. In some embodiments, X 10 is G.
- X 11 is G or G*. In some embodiments, X 11 is G.
- X 12 is G or G*. In some embodiments, X 12 is G.
- At least two of X 10 , X 11 , and X 12 are G or G*. In some embodiments, at least two of X 10 , X 11 , and X 12 are G.
- X 9 is beta A and at least two of X 10 , X 11 , and X 12 are G or G*. In some embodiments, X 9 is beta A and at least two of X 10 , X 1 , and X 12 are G.
- each of X 10 , X 11 , and X 12 are G or G*. In some embodiments, each of X 10 , X 11 , and X 12 are G.
- B is a linking group which is:
- C is a polypeptide that binds HER3.
- C is a polypeptide comprising from about 9 to about 25 amino acids, wherein the polypeptide comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 13.
- C is a polypeptide comprising from about 9 to about 25 amino acids, wherein the polypeptide comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 12:
- cysteine groups refers to a disulfide bond between the cysteine groups (i.e., a cyclized amino acid sequence formed by the disulfide bond between the cysteine groups).
- X 2 is L or L*. In some embodiments, X 2 is L*. In some embodiments, X 2 is L.
- X 3 is P or P*. In some embodiments, X 3 is P. In some embodiments, X 3 is P*.
- X 4 is T or T*. In some embodiments, X 4 is T. In some embodiments, X 4 is T*.
- X 5 is K or K*. In some embodiments, X 5 is K. In some embodiments, X 5 is K*.
- X 6 is F or F*. In some embodiments, X 6 is F. In some embodiments, X 6 is F*.
- X 7 is R or R*. In some embodiments, X 7 is R. In some embodiments, X 7 is R*.
- X 8 is S or S*. In some embodiments, X 8 is S. In some embodiments, X 8 is S*.
- X 2 is L or L*
- X 3 is P or P*
- X 4 is T or T*
- X 5 is K or K*
- X 6 is F or F*
- X 7 is R or R*
- X 8 is S or S*.
- X 2 is L
- X 3 is P
- X 4 is T
- X 5 is K
- X 6 is F
- X 7 is R
- X 8 is S.
- X 2 is L*
- X 3 is P*
- X 4 is T*
- X 5 is K*
- X 6 is F*
- X 7 is R*
- X 8 is S*.
- composition of Formula I is a composition of Formula Ia:
- X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , and X 8 are defined according to the definitions provided herein for compositions of Formula I, and wherein
- composition of Formula I is a composition of Formula Ib:
- A′ is a radioisotope
- X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , and X 8 are defined according to the definitions provided herein for compositions of Formula I, and wherein
- composition of Formula I is a composition of Formula Ic:
- X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , and X 8 are defined according to the definitions provided herein for compositions of Formula I, and wherein
- composition of Formula I is:
- composition of Formula I is a composition of Formula Id:
- Id (SEQ ID NO: 14) A-beta A-G-G-G-C-X 2 -X 3 -X 4 -X 5 -X 6 -X 7 -X 8 -C wherein X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , and X 8 are defined according to the definitions provided herein for compositions of Formula I.
- composition of Formula I is a composition of Formula Ib:
- A′ is a radioisotope
- X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , and X 8 are defined according to the definitions provided herein for compositions of Formula I.
- composition of Formula I is a composition of Formula Ic:
- composition of Formula I is:
- the present application further provides a composition of Formula II: B—C II
- B comprises from about 1 to about 10 amino acids
- compositions of Formula I are defined according to the definition provided herein for compositions of Formula I.
- B comprises a sequence having at least 90% sequence identity to:
- X 9 is beta A.
- X 10 is G or G*. In some embodiments, X 10 is G.
- X 11 is G or G*. In some embodiments, X 11 is G.
- X 12 is G or G*. In some embodiments, X 12 is G.
- At least two of X 10 , X 11 , and X 12 are G or G*. In some embodiments, at least two of X 10 , X 11 , and X 12 are G.
- X 9 is beta A and at least two of X 10 , X 11 , and X 12 are G or G*. In some embodiments, X 9 is beta A and at least two of X 10 , X 11 , and X 12 are G.
- each of X 10 , X 11 , and X 12 are G or G*. In some embodiments, each of X 10 , X 11 , and X 12 are G.
- B is:
- C is a polypeptide comprising from about 9 to about 25 amino acids, wherein the polypeptide comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 13. In some embodiments, C is a polypeptide comprising from about 9 to about 25 amino acids, wherein the polypeptide comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 12. In some embodiments, C is a polypeptide that binds HER3.
- X 2 is L or L*. In some embodiments, X 2 is L*. In some embodiments, X 2 is L.
- X 3 is P or P*. In some embodiments, X 3 is P. In some embodiments, X 3 is P*.
- X 4 is T or T*. In some embodiments, X 4 is T. In some embodiments, X 4 is T*.
- X 5 is K or K*. In some embodiments, X 5 is K. In some embodiments, X 5 is K*.
- X 6 is F or F*. In some embodiments, X 6 is F. In some embodiments, X 6 is F*.
- X 7 is R or R*. In some embodiments, X 7 is R. In some embodiments, X 7 is R*.
- X 8 is S or S*. In some embodiments, X 8 is S. In some embodiments, X 8 is S*.
- X 2 is L or L*
- X 3 is P or P*
- X 4 is T or T*
- X 5 is K or K*
- X 6 is F or F*
- X 7 is R or R*
- X 8 is S or S*.
- X 2 is L
- X 3 is P
- X 4 is T
- X 5 is K
- X 6 is F
- X 7 is R
- X 8 is S.
- X 2 is L*
- X 3 is P*
- X 4 is T*
- X 5 is K*
- X 6 is F*
- X 7 is R*
- X 8 is S*.
- composition of Formula II is a composition of Formula IIa:
- X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , and X 8 are defined according to the definitions provided herein for compositions of Formula II, and wherein
- composition of Formula II is a composition of Formula IIb:
- composition of Formula II is:
- composition of Formula II is:
- the present application further provides a polypeptide suitable for binding HER3.
- the polypeptide comprises from about 9 to about 75 amino acids.
- the polypeptide comprises an amino acid sequence having at least 90% sequence identity to:
- the polypeptide comprises from about 15 to about 25 amino acids, wherein the polypeptide comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 19. In some embodiments, the polypeptide comprises from about 15 to about 25 amino acids, wherein the polypeptide comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 20:
- X 2 is L or L*. In some embodiments, X 2 is L*. In some embodiments, X 2 is L.
- X 3 is P or P*. In some embodiments, X 3 is P. In some embodiments, X 3 is P*.
- X 4 is T or T*. In some embodiments, X 4 is T. In some embodiments, X 4 is T*.
- X 5 is K or K*. In some embodiments, X 5 is K. In some embodiments, X 5 is K*.
- X 6 is F or F*. In some embodiments, X 6 is F. In some embodiments, X 6 is F*.
- X 7 is R or R*. In some embodiments, X 7 is R. In some embodiments, X 7 is R*.
- X 8 is S or S*. In some embodiments, X 8 is S. In some embodiments, X 8 is S*.
- X 2 is L or L*
- X 3 is P or P*
- X 4 is T or T*
- X 5 is K or K*
- X 6 is F or F*
- X 7 is R or R*
- X 8 is S or S*.
- X 2 is L
- X 3 is P
- X 4 is T
- X 5 is K
- X 6 is F
- X 7 is R
- X 8 is S.
- X 2 is L*
- X 3 is P*
- X 4 is T*
- X 5 is K*
- X 6 is F*
- X 7 is R*
- X 8 is S*.
- polypeptide is:
- polypeptide is:
- compositions provided herein can be prepared, for example, according to the procedures described below.
- compositions provided herein comprising polypeptides can be prepared, for example, using standard techniques for the preparation of peptide bonds (e.g., solid-phase synthetic techniques as described in Merrifield et al, Journal of the American Chemical Society 85.14 (1963): 2149-2154).
- Peptide synthetic techniques are well known to those of skill in the art and are described, for example, in Bodanszky et al, Gastroenterology 71 (1976): 965-970; Houghten, Proceedings of the National Academy of Sciences 82.15 (1985): 5131-5135; Stewart et al, Solid phase peptide synthesis. Pierce Chemical Company, 1984.
- polypeptides of the present application may be prepared using solid phase synthetic techniques.
- the amino acid is attached to an inert solid support through its unprotected carboxyl or amino group.
- the protecting group of the amino or carboxyl group is then selectively removed and the next amino acid in the sequence having the complementary (e.g., amino or carboxyl) group suitably protected is admixed and reacted with the residue already attached to the solid support.
- the protecting group of the amino or carboxyl group is then removed from the newly added amino acid residue, and a further amino acid (e.g. an appropriately protected amino acid) is then added. This procedure may be repeated until the desired polypeptide length has been prepared.
- any remaining terminal and side group protecting groups can be removed sequentially or concurrently to provide the final peptide. Additional reactions may be necessary, as described elsewhere, to form intramolecular linkages to restrain conformation.
- Bifunctional cross-linking reagents have been extensively used the preparation of affinity matrices, modification and stabilization of diverse structures, identification of ligand and receptor binding sites, and structural studies.
- Homobifunctional reagents having two identical functional groups have been shown to be highly efficient in cross-linking identical and different polypeptides or residues of a polypeptide, and the linking of polypeptide ligands to their specific binding sites.
- Heterobifunctional reagents contain two different functional groups. By taking advantage of differential reactivity of the different functional groups, cross-linking can be controlled both selectively and sequentially.
- bifunctional cross-linking reagents can be divided according to the specificity of their functional groups, including, but not limited to, amino, sulfhydryl, guanidino, indole, carboxyl specific groups.
- Many heterobifunctional cross-linking reagents contain a primary amine-reactive group and a thiol-reactive group.
- heterobifunctional cross-linking reagents and methods of using the cross-linking reagents are described in U.S. Pat. No. 5,889,155, the disclosure of which is incorporated herein by reference in its entirety.
- the cross-linking reagents combine a nucleophilic hydrazide residue with an electrophilic maleimide residue, allowing coupling in one example, of aldehydes to free thiols.
- the cross-linking reagent can be modified to cross-link various functional groups and is thus useful for cross-linking polypeptides.
- Table 1 details certain hetero-bifunctional cross-linkers considered useful for preparing compositions comprising a group B described herein (e.g., a linking group B as described herein).
- compositions where a particular peptide does not contain a residue amenable for a particular cross-linking reagent in its native sequence conservative genetic or synthetic amino acid changes in the primary sequence can be utilized.
- Radioactively labeled compositions provided herein may be prepared according to well-known methods in the art. For instance, monoclonal antibodies can be iodinated by contact with sodium and/or potassium iodide and a chemical oxidizing agent such as sodium hypochlorite, or an enzymatic oxidizing agent, such as lactoperoxidase.
- compounds of Formula I provided herein may be labeled with 68 Ga by radio metalation of a bifunctional chelator provided herein (e.g., NOTA, DOTA, NODAGA, or NOTA-NCS) or a similar derivative thereof.
- a bifunctional chelator provided herein (e.g., NOTA, DOTA, NODAGA, or NOTA-NCS) or a similar derivative thereof.
- the reactions for preparing compositions described herein can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis.
- suitable solvents can be substantially non-reactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, (e.g., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature).
- a given reaction can be carried out in one solvent or a mixture of more than one solvent.
- suitable solvents for a particular reaction step can be selected by the skilled artisan.
- compositions described herein can involve the protection and deprotection of various chemical groups.
- the need for protection and deprotection, and the selection of appropriate protecting groups, can be readily determined by one skilled in the art.
- the chemistry of protecting groups can be found, for example, in T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 3 rd Ed., Wiley & Sons, Inc., New York (1999).
- Reactions can be monitored according to any suitable method known in the art.
- product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., 1 H or 13 C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), mass spectrometry, or by chromatographic methods such as high performance liquid chromatography (HPLC), liquid chromatography-mass spectroscopy (LCMS), or thin layer chromatography (TLC).
- spectroscopic means such as nuclear magnetic resonance spectroscopy (e.g., 1 H or 13 C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), mass spectrometry, or by chromatographic methods such as high performance liquid chromatography (HPLC), liquid chromatography-mass spectroscopy (LCMS), or thin layer chromatography (TLC).
- HPLC high performance liquid chromatography
- LCMS liquid chromatography-mass spectroscopy
- TLC thin layer chromatography
- Compositions can be purified by
- divalent linking substituents are described. It is specifically intended that each divalent linking substituent include both the forward and backward forms of the linking substituent.
- —NR(CR′R′′) n -includes both —NR(CR′R′′) n — and —(CR′R′′) n NR—.
- the Markush variables listed for that group are understood to be linking groups.
- Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton.
- Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge.
- Example prototropic tautomers include ketone—enol pairs, amide—imidic acid pairs, lactam—lactim pairs, enamine—imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, for example, 1H— and 3H-imidazole, 1H—, 2H— and 4H-1,2,4-triazole, 1H— and 2H-isoindole, and 1H— and 2H-pyrazole.
- Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.
- compounds and compositions provided herein can also include all isotopes of atoms occurring in the intermediates or final compounds.
- Isotopes include those atoms having the same atomic number but different mass numbers.
- an atom is designated as an isotope or radioisotope (e.g., deuterium, [ 11 C], [ 18 F])
- the atom is understood to comprise the isotope or radioisotope in an amount at least greater than the natural abundance of the isotope or radioisotope.
- an atom is designated as “D” or “deuterium”, the position is understood to have deuterium at an abundance that is at least 3000 times greater than the natural abundance of deuterium, which is 0.015% (i.e., at least 45% incorporation of deuterium).
- preparation of compounds and compositions described herein can involve the addition of acids or bases to affect, for example, catalysis of a desired reaction or formation of salt forms such as acid addition salts.
- Example acids can be inorganic or organic acids and include, but are not limited to, strong and weak acids.
- Some example acids include hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, p-toluenesulfonic acid, 4-nitrobenzoic acid, methanesulfonic acid, benzenesulfonic acid, trifluoroacetic acid, and nitric acid.
- Some weak acids include, but are not limited to acetic acid, propionic acid, butanoic acid, benzoic acid, tartaric acid, pentanoic acid, hexanoic acid, heptanoic acid, octanoic acid, nonanoic acid, and decanoic acid.
- Example bases include lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium carbonate, sodium carbonate, potassium carbonate, and sodium bicarbonate.
- Some example strong bases include, but are not limited to, hydroxide, alkoxides, metal amides, metal hydrides, metal dialkylamides and arylamines, wherein; alkoxides include lithium, sodium and potassium salts of methyl, ethyl and t-butyl oxides; metal amides include sodium amide, potassium amide and lithium amide; metal hydrides include sodium hydride, potassium hydride and lithium hydride; and metal dialkylamides include lithium, sodium, and potassium salts of methyl, ethyl, n-propyl, iso-propyl, n-butyl, tert-butyl, trimethylsilyl and cyclohexyl substituted amides.
- the compounds (e.g., polypeptides) and compositions provided herein are substantially isolated.
- substantially isolated is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected.
- Partial separation can include, for example, a composition enriched in the compounds provided herein.
- Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compounds provided herein, or salt thereof. Methods for isolating compounds and compositions are routine in the art.
- phrases “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- non-natural amino acid refers to any derivative of a natural amino acid including D forms, and ⁇ and ⁇ amino acid derivatives. It is noted that certain amino acids, e.g., hydroxyproline, that are classified as a non-natural amino acid herein, may be found in nature within a certain organism or a particular protein.
- non-natural amino acids or amino acid derivatives may be constituents of the compositions described herein (common abbreviations are in parentheses): ⁇ -Alanine (beta A, ⁇ -Ala, ⁇ A, or ⁇ -A), ⁇ -Aminobutyric Acid (GABA), 2-Aminobutyric Acid (2-Abu), ⁇ , ⁇ -Dehydro-2-aminobutyric Acid ( ⁇ -Abu), 1-Aminocyclopropane-1-carboxylic Acid (ACPC), Aminoisobutyric Acid (Aib), 2-Amino-thiazoline-4-carboxylic Acid, 5-Aminovaleric Acid (5-Ava), 6-Aminohexanoic Acid (6-Ahx), 8-Aminooctanoic Acid (8-Aoc), 11-Aminoundecanoic Acid (11-Aun), 12-Aminododecanoic Acid (12-Ad
- Stereochemistry of amino acids may be designated by preceding the name or abbreviation with the designation “D”, “d”, “L”, or “1” as appropriate. Additionally, ⁇ N-alkylated amino acids may be employed, as well as amino acids having amine-containing side chains (such as Lys and Orn) in which the amine has been acylated or alkylated.
- the present application further provides methods of imaging HER3.
- the method of imaging is performed in a cell, a tissue, a cell sample, a tissue sample, or a subject.
- the term “subject,” refers to any animal, including mammals and invertebrates. For example, mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, primates, fish, and humans.
- the subject is a human.
- the subject is a mouse.
- the method comprises administering to the subject an effective amount of a composition provided herein (e.g., a composition of Formula I).
- the method is an in vitro method.
- the method is an in vivo method.
- the present application provides a method of imaging cancer in a subject, the method comprising:
- compositions provided herein e.g., a composition of Formula I
- the present application further provides a method of treating a cancer in a subject, the method comprising:
- compositions provided herein e.g., a composition of Formula I
- the present application further provides a method of monitoring treatment of a cancer in a subject, the method comprising:
- compositions provided herein e.g., a composition of Formula I
- the methods provided herein further comprise administering an additional effective amount of the composition to the subject after step iii).
- the methods provided herein further comprise imaging the subject with a suitable imaging technique after step iii).
- the methods provided herein further comprise waiting a time sufficient to allow the compound to accumulate at a cell or tissue site (e.g., a cell or tissue site in a subject) associated with the disease, prior to imaging. In some embodiments, the methods provided herein further comprise waiting a time sufficient to allow the compound to bind HER3 at a cell or tissue site (e.g., a cell or tissue site in a subject) associated with the cancer, prior to imaging.
- the time sufficient is from about 30 seconds to about 24 hours, for example, about 30 seconds to about 24 hours, about 30 seconds to about 12 hours, about 30 seconds to about 6 hours, about 30 seconds to about 2 hours, about 30 seconds to about 1 hour, about 30 seconds to about 30 minutes, about 30 seconds to about 10 minutes, about 10 minutes to about 24 hours, about 10 minutes to about 12 hours, about 10 minutes to about 6 hours, about 10 minutes to about 2 hours, about 10 minutes to about 1 hour, about 10 minutes to about 30 minutes, about 30 minutes to about 24 hours, about 30 minutes to about 12 hours, about 30 minutes to about 6 hours, about 30 minutes to about 2 hours, about 30 minutes to about 1 hour, about 1 hour to about 24 hours, about 1 hour to about 12 hours, about 1 hour to about 6 hours, about 1 hour to about 2 hours, about 2 hours to about 24 hours, about 2 hours to about 12 hours, about 2 hours to about 6 hours, about 6 hours to about 24 hours, about 6 hours to about 12 hours, or about 12 hours to about 24 hours.
- the cancer is a solid tumor.
- the cancer is selected from the group consisting of breast cancer, lung cancer, prostate cancer, gastric cancer, head and neck cancer, and ovarian cancer.
- the cancer is selected from the group consisting of breast cancer, lung cancer, and prostate cancer.
- the cancer is prostate cancer.
- the prostate cancer is castration resistant prostate cancer.
- the cancer is breast cancer.
- the imaging technique is selected from the group consisting of magnetic resonance (MR) imaging, positron emission tomography (PET) imaging, fluorescent imaging, single photon emission computed tomography (SPECT), luminescent imaging, or any combination thereof.
- the imaging technique is selected from the group consisting of magnetic resonance (MR) imaging, positron emission tomography (PET) imaging, or a combination thereof.
- the imaging technique is positron emission tomography (PET) imaging.
- the phrase “therapeutically effective amount” refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response that is being sought in a tissue, system, animal, individual or human by a researcher, veterinarian, medical doctor or other clinician.
- treating refers to one or more of (1) inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., arresting further development of the pathology and/or symptomatology); and (2) ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/or symptomatology) such as decreasing the severity of disease or reducing or alleviating one or more symptoms of the disease.
- compositions provided herein can be administered in combination with one or more of the additional therapeutic agents provided herein.
- additional therapeutic agents include, but are not limited to, anesthetic agents (e.g., for use in combination with a surgical procedure), chemotherapeutic agents, and therapeutic antibodies.
- the additional therapeutic agent is an anesthetic agent.
- exemplary anesthetic agents include, but are not limited to, local anesthetics (e.g., lidocaine, procain, ropivacaine) and general anesthetics (e.g., desflurane, enflurane, halothane, isoflurane, methoxyflurane, nitrous oxide, sevoflurane, mmobarbital, methohexital, thiamylal, thiopental, diazepam, lorazepam, midazolam, etomidate, ketamine, propofol, alfentanil, fentanyl, remifentanil, buprenorphine, butorphanol, hydromorphone levorphanol, meperidine, methadone, morphine, nalbuphine, oxymorphone, pentazocine).
- local anesthetics e.g.,
- the additional therapeutic agent is a chemotherapeutic agent.
- chemotherapeutic agents include, but are not limited to, cisplatin, doxorubicin, taxol, etoposide, irinotecan, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methotrexate, temozolomide, cyclophosphamide, tipifarnib, gefitinib, erlotinib, imatinib, gemcitabine, uracil mustard, chlormethine, ifosfamide, melphalan, chlorambucil, pipobroman, triethylenemelamine, busulfan, carmustine, lomustine, streptozocin, dacarbazine, floxuridine, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, oxa
- Exemplary therapeutic antibodies include, but are not limited to, patritumab, lumretuzumab, trastuzumab, pertuzumab, MM-121, U3-1402, AV-203, and GSK2849330.
- the therapeutic agent is a HER3 inhibitor.
- the therapeutic agent is selected from the group consisting of patritumab, MM-121, U3-1402, GSK2849330, neratinib, lumretuzumab, U3-1287, Sym013, AV-203, and erlotinib.
- the therapeutic agent is a HER2 inhibitor.
- the HER2 inhibitor is selected from the group consisting of lapatinib, trastuzumab, pertuzumab, and erlotinib.
- the therapeutic agent is a PI3K inhibitor.
- the PI3K inhibitor is GDC-0941.
- the therapeutic agent is a AKT inhibitor.
- the AKT inhibitor is GDC-0068.
- the therapeutic agent is an androgen receptor antagonist.
- the androgen receptor antagonist is enzalutamide.
- the therapeutic agent is a gonadotrophin-releasing hormone antagonist.
- the gonadotrophin-releasing hormone antagonist is cetrorelix.
- the additional therapeutic agent is administered simultaneously with a composition provided herein. In some embodiments, the additional therapeutic agent is administered after administration of the composition provided herein.
- the additional therapeutic agent is administered prior to administration of the composition herein. In some embodiments, the composition provided herein is administered during a surgical procedure. In some embodiments, the composition provided herein is administered in combination with an additional therapeutic agent during a surgical procedure.
- the additional therapeutic agents provided herein can be effective over a wide dosage range and are generally administered in an effective amount. It will be understood, however, that the amount of the therapeutic agent actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be imaged, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual subject, the severity of the subject's symptoms, and the like.
- compositions and therapeutic agents provided herein can be administered in the form of pharmaceutical formulations.
- These formulations can be prepared as described herein or elsewhere, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated.
- the administration is selected from the group consisting of pulmonary administration (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer, intratracheal administration, or intranasal administration), oral administration, or parenteral administration (e.g., intravenous, intraarterial, subcutaneous, intraperitoneal, intramuscular or injection or infusion, intracranial, intrathecal, intraventricular administration, and the like).
- the administration is intravenous or nasal administration.
- Parenteral administration can be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump.
- Conventional pharmaceutical carriers, aqueous, powder, or oily bases, thickeners and the like, may be necessary or desirable.
- compositions which contain, as the active ingredient, a composition provided herein in combination with one or more pharmaceutically acceptable carriers (excipients).
- excipients a pharmaceutically acceptable carriers
- the nanoparticle composition may be, for example, mixed with an excipient or diluted by an excipient.
- the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier, or medium for the nanoparticle composition.
- the pharmaceutical formulations can be in the form of powders, lozenges, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), sterile injectable solutions, sterile packaged powders, and the like.
- MDA-MB-453, HCC1954 and 22Rvl cells were purchased from American Type Culture Collection (Manassas, Va.) and cultured in RPMI-1640 media supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin.
- a cysteine-constrained randomized 7-mer library (New England Biolabs, Ipswich, Mass.) was utilized for the phage display selection.
- HER3 extracellular domain (ECD) (R&D Systems, Minneapolis, Minn.) was conjugated with long chain biotin (Thermo Scientific, Waltham, Mass.) utilizing standard NHS ester chemistry and purified by size exclusion chromatography with a 10 kDa molecular weight cut-off column (Genesee Scientific, San Diego, Calif.).
- HER3 ECD and bovine serum albumin as a control were adsorbed to Nunc Maxisorp 96 well plates (Sigma, St. Louis, Mo.). Supernatants corresponding to individual phages were added to HER3 and BSA wells and allowed to bind for 1 h at 37° C. Following binding, wells were washed 6 times with TBST and bound phage were detected by the addition of a horseradish peroxidase (HRP)-conjugated anti-M13 antibody.
- HRP horseradish peroxidase
- ABTS 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)
- ELISA was performed in the exact same manner and the absorbance of each phage to either HER3 or BSA was quantified by spectrophotometer. Phagemid DNA from each of the five phages in addition to three phages with no binding per the initial ELISA were recovered by plasmid miniprep isolation and automated Sanger DNA sequencing was performed by the CCIB DNA Core Facility at Massachusetts General Hospital (Cambridge, Mass.).
- all 5 were sequenced to ascertain the amino acid composition of their displayed peptide.
- each of the sequenced phage displayed an identical peptide.
- three phage which did not demonstrate HER3 specific binding were also sequenced, and each had a different peptide sequence than the convergent sequence, as shown in FIG. 1C .
- the peptide sequence was covalently linked to a biotin-conjugated N-terminal tri-glycine linker using standard Fmoc chemistry. The purity and molecular weight were determined by high performance liquid chromatography and mass spectrometry. In order to confirm HER3 affinity, the peptide was analyzed for binding to HER3 ECD immobilized to Nunc Maxisorp 96 well microtiter plates. Following blocking with 1% non-fat dry milk, increasing concentrations of peptide were incubated with target protein for 1 h at 37° C.
- HER3P1 bound in a sigmoidal manner, with an affinity of 270 ⁇ 151 nM, as shown in FIG. 2A .
- the absorbance of HER3P1 binding to HER3 was 0.82 ⁇ 0.03, whereas binding to EGFR was 0.21 ⁇ 0.09, HER2 was 0.22 ⁇ 0.07 and BSA was 0.15 ⁇ 0.01 (P ⁇ 0.001 for all), indicating that the peptide was highly specific for HER3 and suitable for cell binding analysis, as shown in FIG. 2B .
- MDA-MB-453 breast cancer cells which express moderate levels of HER3 and HCC-1954 cells which express low levels of HER3, were chosen to assess the ability of the peptide to discriminate between relatively close expression levels in vitro.
- Cells were seeded at a density of 1 ⁇ 10 5 cells/well in 96 well plates (Fisher) and grown overnight for 24 h in fetal bovine serum supplemented medium.
- HER3 peptide or a control peptide were added at 250 nM in media and incubated for 1 h at 37° C. Cells were washed 3 ⁇ with PBS and bound peptide detected by addition of streptavidin-HRP.
- MDA-MB-453 and HCC-1954 cells were fixed in 10% formalin and dried onto microscope slides overnight. Following rehydration with TBS, slides were blocked with 2% BSA in TBS for 1 h prior to addition of peptide at a concentration of 250 nM in 0.1% TBST and incubation at room temperature for 1 h. Cells were washed 3 ⁇ with 0.1% TBST and neutravidin-Alexafluor488 was added to cells and incubated at room temperature for 1 h. Cells were washed, mounted with Vectorshield mounting media with DAPI (Vector Labs, Burlingame, Calif.) and visualized by inverted microscope (Olympus, Tokyo, Japan).
- DAPI Vector Labs, Burlingame, Calif.
- HER3P1 Cell binding for HER3P1 was quantified and absorbance for MDA-MB-453 was 0.29 ⁇ 0.06, whereas it was significantly lower for HCC-1954 cells 0.13 ⁇ 0.06 (P ⁇ 0.05). Additionally HER3P1 binding was significantly higher to MDA-MB-453 cells than the control peptide (0.12 ⁇ 0.06, P ⁇ 0.05), whereas there was no difference between the control peptide and the HER3P1 for binding to HCC-1954 cells, as shown in FIG. 3A . The strong selectivity of the peptide was also apparent using fluorescent microscopy, with high binding to MDA-MB-453 cells and almost no visualization of HCC-1954 cells, as shown in FIG. 3B .
- a NOTA-NCS conjugated HER3 peptide was synthesized in the same manner as the biotinylated peptide, with NOTA-NCS being substituted for biotin.
- the peptide was radio labeled with the radiometal 68 Ga eluted from a 68 Ge/ 68 Ga generator (iThemba, South Africa) in 0.05M HCl.
- Peptide was purified from free 68 Ga by reverse phase C18 cartridge (Waters, Milford, Mass.) and purity determined by ITLC. The peptide was then prepared in normal saline to a specific activity of approximately 300 MBq/mg for injection into mice. Nu/nu mice bearing either 22RV1 (high HER3 expressing prostate cancer) or HCC-1954 (low HER3 expressing breast cancer) tumors were implanted in the right upper flank of mice and grown to approximately 5-7 mm. Radiolabeled HER3 peptide was injected intravenously and allowed to circulate for 1 h prior to PET imaging. PET images were acquired on an Inveon micro PET/CT (Siemens, Knoxville, Tenn.) for 15 minutes in list mode, followed by CT acquisition.
- Inveon micro PET/CT Siemens, Knoxville, Tenn.
- the tumor and blood uptake was calculated in a 3D region of interest drawn around the tumor and heart, respectively, using CT guidance. Images were post-processed using VivoQuant (InviCRO, Boston, Mass.).
- HER3 sc-81455, Santa Cruz Biotech, Dallas, Tex.
- ⁇ -actin 13E5, Cell Signaling, Danvers, Mass.
- Abeam HRP-conjugated goat-anti-rabbit secondary antibody
- Cell Signaling SignalFire chemiluminescent substrate
- PET imaging demonstrated high 68 Ga—(NOTA-NCS)-HER3P1 tumor uptake in 22RV1 tumor bearing mice, with much lower levels in HCC-1954 tumor bearing mice, as shown in FIG. 4A .
- Off-target peptide accumulation was minimal, with uptake in the kidneys and bladder consistent with the normal route of peptide clearance.
- HER3 and ⁇ -actin were quantified by Western blot, as shown in FIG. 4B .
- Sites of accumulation included the HER3+ tumors (0.50 ⁇ 0.18% ID/g) and HER3+ organs such as the stomach (0.30 ⁇ 0.07% ID/g), intestines (0.48 ⁇ 0.15% ID/g) and lungs (0.70 ⁇ 0.14% ID/g), in addition to kidneys (10.1 ⁇ 1.67% ID/g) as a route of clearance, as shown in FIG. 5A .
- Accumulation in off-target organs was not due to blood accumulation, as tumor:organ ratios were significantly lower than tumor:blood ratios (P ⁇ 0.05 stomach, P ⁇ 0.001 intestines and lungs, as shown in FIG. 5B .
- Comparison between PET TBR and biodistribution TBR was highly correlated, as determined using a Pearson correlation (P ⁇ 0.001), as shown in FIG. 5C .
- HER3P1 demonstrated excellent tumor to background ratios (1.59-3.32) in HER3+ tumors which were significantly higher than the low HER3 expressing control tumors (0.84-0.93). Furthermore, ex vivo analysis of imaged tumors revealed a high (P ⁇ 0.001) correlation between HER3 peptide uptake and both HER3 protein expression and percent injected dose per gram. These results indicate that HER3P1 represents a promising, clinically translatable HER3 imaging agent, and future translational efforts are being sought. PET imaging also revealed high tumor to blood ratios in the HER3 positive 22RV1 cell line, with background levels in HER3-negative HCC-1954 tumors. Furthermore, ex vivo analysis of the tumors used for PET imaging provided a highly significant correlation between protein expression and PET TBR, indicating an accurate and robust method of HER3 quantification suitable for exploration in both pre-clinical and clinical trials.
- a competitive binding assay was also performed according to the following procedures. Ten ⁇ Ci of purified 68 Ga-HER3P1 was added to 1 ⁇ 10 5 MDA-MB-453 cells and incubated for 1 h. After incubation, cells were washed 3 ⁇ with TBS and bound radioactivity quantified by a Wallac gamma counter (Perkin Elmer, Waltham, Mass.). As a control, excess (100 ⁇ M) peptide was added to cells and bound peptide measured in the same manner. The 68 Ga-HER3P1 bound to MDA-MB-453 cells and binding was significantly (P ⁇ 0.05) blocked by the addition of excess unlabeled (NOTA-NCS)-HER3P1, indicating specific peptide binding, as shown in FIG. 3C .
- Parent peptide sequence C-L-P-T-K-F-R-S-C (SEQ ID NO.: 1) was mutated at positions 2-8 to an alanine, and binding of the phage to HER3 was assessed.
- the results, shown in FIG. 6 illustrate that for positions 2-4 and 7-8, substitution to alanine diminished binding to HER3 by 50% or greater. In contrast, positions 5-6 were unaffected by the mutation. This data demonstrates that amino acids 2-4 and 7-8 are involved in peptide binding, whereas 5 and 6 are amenable to mutation.
- mice bearing human MDA-MB-453 tumors were injected with 68 Ga—(NOTA-NCS)-HER3P1 and subjected to PET imaging. Following imaging, mice were treated with 100 mg/kg of lapatinib every 12 hours for 48 hours following PET imaging. At the end of 48 hours, mice were imaged in the exact same manner as before treatment.
- SUV mean levels of HER3P1 increased to 1.35 ⁇ 0.59, as shown in FIG. 7 .
- Representative images from one of the mice is shown in FIG. 8 .
- HER3P1 PET imaging will allow for non-invasive quantification of HER3 receptor expression level changes in response to PI3K inhibition, facilitating rapid analysis of HER3 mediated resistance across a panel of triple negative breast cancers (TNBCs).
- TNBCs triple negative breast cancers
- a panel of TNBC cell lines considered sensitive or resistant to PI3K inhibition with GDC-0941 (IC 50 ⁇ 1 ⁇ M) (Sensitive: HDQ-P1, CAL-51, HCC-70, CAL-148, HCC-1395, HS-578T, CAL-148; Resistant: MDA-MB-468, MDA-MB-231, MDA-MB-157, BT-549, CAL-120) (see e.g., O'Brien et al, Clin Cancer Res. 2010, 16:3670-3683) will be treated with GDC-0941.
- the selected cell lines are reflective of the genetic heterogeneity of TNBC, with all dominant genetic categories represented (PI3KCA mutations, PTEN loss, KRAS mutant, EGFR overexpression).
- the cell lines will be treated with the PI3K inhibitor GDC-0941 and Western blot will be used to assess expression and phosphorylation status of HER3, as well as downstream growth signaling proteins (PI3K, AKT, mTOR, S6K, ERK) to assess for persistent signaling after PI3K inhibition.
- whole cell viability and proliferation will also be analyzed using Celltiter-Glo. Eight cell lines will be selected for further in vivo analysis.
- Cell lines will include two sensitive cell line without HER3 upregulation, two sensitive cell line demonstrating HER3 upregulation, two resistant cell lines without HER3 upregulation after treatment, and two resistant cell lines with HER3 upregulation after treatment.
- xenografts of the selected tumors will be implanted in nu/nu female mice. Once tumors measure 5 mm in diameter, mice will be imaged by PET/CT with 68 GA-HER3P1 (i.e., 68 Ga—(NOTA-NCS)HER3P1), according to our previously established protocols (see e.g., Wehrenberg-Klee et al, Journal of Nuclear Medicine, 2016, 57(9): 1413-1419).
- mice will be randomized to 48 h treatment with 75 mg/kg GDC-0941 or vehicle. 48 h following treatment initiation, mice will be injected with 68 Ga-HER3P1, and PET imaged again as described above. To confirm accurate quantification of HER3 expression by our HER3 PET probe, as well as similar biochemical response to PI3K inhibition in vivo as defined during in vitro cell analysis, mice will be sacrificed following final imaging and tumors harvested. Radioactivity of excised tumors will be immediately measured by gamma counter. Following radioactive decay, tumor will be homogenized, lysed and the tumor lysate analyzed by Western blot as above.
- Example 9 Using Imaged HER3 Upregulation Patterns, Test Efficacy of HER3 Inhibitor Addition to Inhibit TNBC Growth In Vitro and In Vivo
- HER3 PET imaging From the eight cell lines identified for HER3 PET imaging in Example 8, a subset of four cell lines including one sensitive cell line without HER3 upregulation, one sensitive cell line demonstrating HER3 upregulation, one resistant cell line without HER3 upregulation after treatment, and one resistant cell line with HER3 upregulation after treatment will be analyzed in order to correlate imaging findings to proliferation and growth responses.
- Each cell line will be treated with PI3K inhibitor, PI3K inhibitor with additional HER3 inhibitor, or vehicle. Efficacy of treatment regimens overtime will be assessed with viability (MTT, Presto Blue, WST-1) and clonogenic (Crystal violet) assays. Growth pathway inhibition will be assessed by Western blot.
- the same cell lines selected for in vitro analysis will also be analyzed in vivo.
- mice bearing cell line xenografts will be treated with vehicle, single agent PI3K inhibitor, or PI3K inhibitor with the addition of HER3 inhibitor. Tumor volumes will be measured three times a week. Experiments will terminate when significant differences in tumor growth are recorded between the treatment arms and/or the tumor volumes reach size requiring euthanasia. These experiments will also inform on treatment tolerability. Tumors will be harvested at the end of the experiments to confirm target inhibition. Conventionally, we will always collect tissue samples two hours from the last drug administration to allow both intra- and inter-experimental comparisons.
- samples When possible (xenografts are not too small and/or fibrotic), samples will be analyzed by Western blot against the total and phosphorylated forms of the targeted RTKs and signaling pathway effectors (phosphoAKT, phosphoPRAS40, phosphoS6K, phospho4EBP1). Moreover, the same analyses will be validated by immunohistochemistry (IHC). IHC will also be used to measure the nuclear/cytosolic ratio of FOXO, a known transcription factor responsible for HER3 upregulation upon PI3K inhibition.
- IHC immunohistochemistry
- Example 10 TNBC Patient-Derived Xenograft HER3 PET Imaging and Treatment with PI3K Inhibitor and Image Guided Therapy
- FFPE paraffin-embedded
- mice bearing PDXs Female nude mice bearing PDXs will be used to implant subsequent mice for all studies. Tumors will be imaged with 68 Ga-HER3P1 and randomized to treatment with GDC-0941 (PI3K inhibitor) or vehicle. Following two days of treatment, the mice will undergo repeat 68 Ga-HER3P1 imaging, as previously described, and tumoral HER3 PET SUV will be measured. The GDC-0941 group will then be randomized to receive additional HER3 inhibitor or additional vehicle. Following the initiation of secondary treatment, tumor volumes will be measured by caliper at least three times a week. Experiments will be carried out for 35 days following the beginning of secondary treatment, or when the tumor volumes reach unethical size. Tumors will be harvested at the end of the experiments to confirm target inhibition.
- GDC-0941 PI3K inhibitor
- samples will be analyzed ex vivo by Western blot when possible against the total and phosphorylated forms of HER3 as well as downstream signaling proteins as described above. IHC samples will also be analyzed following previously described technique.
- a panel of TNBC cell lines considered sensitive or resistant to AKT inhibition with GDC-0068 (IC 50 ⁇ 1 ⁇ M) (Sensitive: CAL-148, HCC-70, CAL-51, HCC-1395, HS-578T; Resistant: MDA-MB-468, HC-143, CAL-85-1, HDQ-P1, MDA-MB-231, BT-549) 4,37 will be treated with GDC-0068.
- the identical cell signaling and viability assays performed in Examples 8-10, will be performed in Example 11 to compare the effects of AKT inhibition. For each therapy, four cell lines will be selected for further in vivo analysis.
- Cell lines will include a sensitive cell line without HER3 upregulation, a sensitive cell line demonstrating the most HER3 upregulation, a resistant cell line without HER3 upregulation after treatment, and a resistant cell line with HER3 upregulation after treatment.
- xenografts of the selected tumors will be implanted in nu/nu female mice and PET images will be acquired and data analyzed in the same manner as detailed in Examples 8-10.
- mice will be randomized to 48 h treatment with 75 mg/kg GDC-0068 or vehicle. 48 h following treatment initiation, mice will be injected with 68 Ga-HER3P1 and again imaged with image analysis as per Example 8.
- mice will be sacrificed, tumors harvested and the tumor lysate analyzed by Western blot as above.
- Example 12 Imaged HER3 Upregulation Patterns in Response to AKT Inhibition, Test Efficacy of HER3 Inhibitor Addition to Inhibit TNBC Growth Both In Vitro and In Vivo
- Example 11 From the eight cell lines identified for HER3 PET imaging in Example 11, a subset of four cell lines including one sensitive cell line without HER3 upregulation, one sensitive cell line demonstrating HER3 upregulation, one resistant cell line without HER3 upregulation after treatment, and one resistant cell line with HER3 upregulation after treatment will be analyzed in order to correlate imaging findings to proliferation and growth responses.
- In vitro studies of treatment efficacy for HER3 inhibitor combination therapies will be systematically conducted as in Example 9. The same cell lines selected for in vitro analysis will also be analyzed in vivo. Female nu/nu mice bearing cell line xenografts will be treated with vehicle, single agent AKT inhibitor, or AKT inhibitor with the addition of HER3 inhibitor. Tumor volumes will be measured and following completion of study excised tumors will be assessed as in Example 9.
- TNBC PDX lines will be utilized, as outlined in Example 10. Tumors will be imaged with HER3P1 and then randomized to treatment with the AKT inhibitor GDC-006875 mg/kg or vehicle. Following two days of treatment, the mice will undergo repeat imaging, as previously described, and tumoral HER3 PET SUV will be measured. GDC-0068 treated tumors will then be randomized to receive HER3 inhibitor therapy or vehicle. Following the initiation of secondary treatment, tumor volumes will be measured for 35 days following the beginning of secondary treatment, or when the tumor volumes reach unethical size. Tumors will be harvested at the end of the experiments to confirm target inhibition.
- samples will be analyzed ex vivo by Western blot when possible against the total and phosphorylated forms of HER3 as well as downstream signaling proteins as described above. IHC samples will also be analyzed following previously described technique.
- HER2+ breast cancer cell lines either sensitive to HER2 inhibition (BT-474, SKBR3, UACC812, UACC893, ZR-75-30) 47 or resistant to HER2 inhibition (JIMT-1, MDA-MB-453, HCC1569, HCC1954, MDA-MB-361) (see e.g., Wang et al, Breast Cancer Res. 2011, 13: R121), and including the dominant mutations found in HER2+ breast cancer (PI3KCA mutations, PTEN loss) will be treated with standard treatment dose of the HER2 inhibitor lapatinib (1 ⁇ M) or vehicle for 48 h.
- HER3 and HER2 will be assessed by Western blot, and quantified as described above.
- Cell viability (Celltiter-Glo) assays will be performed to monitor the effects of lapatinib treatment on proliferation. After in vitro analysis, a total of four cell lines will be selected for further in vivo imaging analysis. The identical cell signaling and viability assays performed in Examples 8-10, will be performed in this Example to compare the effects of AKT inhibition. For each therapy, four cell lines will be selected for further in vivo analysis.
- Cell lines will include a sensitive cell line without HER3 upregulation, a sensitive cell line demonstrating the most HER3 upregulation, a resistant cell line without HER3 upregulation after treatment, and a resistant cell line with HER3 upregulation after treatment.
- xenografts of the selected tumors will be implanted in nu/nu female mice, randomized to 48 h treatment with lapatinib or vehicle. Following treatment initiation, mice will be injected with dose of HER3 PET Probe. PET imaging data will be obtained and analyzed as described in Examples 8-10. Tumors will be excised and tumor and analyzed by Western blot for expression and phosphorylation of HER3 and downstream signaling proteins as described for in vitro studies.
- Example 14 The four cell lines identified for HER3 PET imaging in Example 14 will be used for treatment experiments. For each cell line, in vitro studies of treatment efficacy for HER3 inhibitor and HER2 inhibitor combination regimens will be conducted in the same manner as Examples 9 and 12. Following in vitro analysis, groups of female nu/nu mice bearing cell-line xenografts will be treated with control, lapatinib, or the combination of lapatinib and HER3 inhibitor, tumor volumes measured, and when possible tumors excised an analyzed ex vivo to determine the molecular signatures of effective therapy and resistance outlined in Example 14.
- HER2+ PDX lines will be established in a manner similar to Examples 10 and 13.
- Female nude mice bearing PDXs will be PET imaged and then randomized to treatment with lapatinib or vehicle. Following two days of treatment, the mice will be undergo repeat HER3 PET imaging. The lapatinib arm will then be further randomized to receive either HER3 inhibitor therapy in addition to previously assigned therapy, or additional vehicle.
- tumor volumes will be measured by caliper three times a week. Experiments will be carried out for 35 days following the beginning of secondary treatment, or when the tumor volumes reach unethical size. Tumors will be harvested at experiment end to confirm target inhibition. Samples will be analyzed ex vivo by Western blot when possible against the total and phosphorylated forms of HER3 as well as downstream signaling proteins as described above. IHC samples will also be analyzed following previously described technique.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/475,020 US11241511B2 (en) | 2016-12-29 | 2017-12-29 | HER3 peptides for imaging and radiotherapy |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662440052P | 2016-12-29 | 2016-12-29 | |
PCT/US2017/069031 WO2018126183A2 (fr) | 2016-12-29 | 2017-12-29 | Peptides her3 pour imagerie et radiothérapie |
US16/475,020 US11241511B2 (en) | 2016-12-29 | 2017-12-29 | HER3 peptides for imaging and radiotherapy |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/069031 A-371-Of-International WO2018126183A2 (fr) | 2016-12-29 | 2017-12-29 | Peptides her3 pour imagerie et radiothérapie |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/562,861 Division US20220175975A1 (en) | 2016-12-29 | 2021-12-27 | HER3 Peptides for Imaging and Radiotherapy |
Publications (2)
Publication Number | Publication Date |
---|---|
US20200121814A1 US20200121814A1 (en) | 2020-04-23 |
US11241511B2 true US11241511B2 (en) | 2022-02-08 |
Family
ID=62710947
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/475,020 Active US11241511B2 (en) | 2016-12-29 | 2017-12-29 | HER3 peptides for imaging and radiotherapy |
US17/562,861 Pending US20220175975A1 (en) | 2016-12-29 | 2021-12-27 | HER3 Peptides for Imaging and Radiotherapy |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/562,861 Pending US20220175975A1 (en) | 2016-12-29 | 2021-12-27 | HER3 Peptides for Imaging and Radiotherapy |
Country Status (2)
Country | Link |
---|---|
US (2) | US11241511B2 (fr) |
WO (1) | WO2018126183A2 (fr) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
US4938948A (en) | 1985-10-07 | 1990-07-03 | Cetus Corporation | Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies |
US5021236A (en) | 1981-07-24 | 1991-06-04 | Schering Aktiengesellschaft | Method of enhancing NMR imaging using chelated paramagnetic ions bound to biomolecules |
US5889155A (en) | 1992-08-05 | 1999-03-30 | Genentech, Inc. | Carbohydrate-directed cross-linking reagents |
US20130137774A1 (en) | 2010-06-02 | 2013-05-30 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to her2/neu receptor complex |
US20150252079A1 (en) | 2012-10-05 | 2015-09-10 | Affibody Ab | Her3 binding polypeptides |
US20150265733A1 (en) | 2008-03-07 | 2015-09-24 | Universität Bern | Bombesin analog peptide antagonist conjugates |
-
2017
- 2017-12-29 WO PCT/US2017/069031 patent/WO2018126183A2/fr active Application Filing
- 2017-12-29 US US16/475,020 patent/US11241511B2/en active Active
-
2021
- 2021-12-27 US US17/562,861 patent/US20220175975A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5021236A (en) | 1981-07-24 | 1991-06-04 | Schering Aktiengesellschaft | Method of enhancing NMR imaging using chelated paramagnetic ions bound to biomolecules |
US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
US4938948A (en) | 1985-10-07 | 1990-07-03 | Cetus Corporation | Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies |
US5889155A (en) | 1992-08-05 | 1999-03-30 | Genentech, Inc. | Carbohydrate-directed cross-linking reagents |
US20150265733A1 (en) | 2008-03-07 | 2015-09-24 | Universität Bern | Bombesin analog peptide antagonist conjugates |
US20130137774A1 (en) | 2010-06-02 | 2013-05-30 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to her2/neu receptor complex |
US20150252079A1 (en) | 2012-10-05 | 2015-09-10 | Affibody Ab | Her3 binding polypeptides |
Non-Patent Citations (24)
Also Published As
Publication number | Publication date |
---|---|
WO2018126183A3 (fr) | 2018-08-23 |
US20200121814A1 (en) | 2020-04-23 |
WO2018126183A2 (fr) | 2018-07-05 |
US20220175975A1 (en) | 2022-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11607466B2 (en) | Tumor and immune cell imaging based on PD-L1 expression | |
US11638765B2 (en) | Double-labeled probe for molecular imaging and use thereof | |
EP3502122B1 (fr) | Peptide cible de tumeur maligne | |
US20130330274A1 (en) | Compositions and methods for detecting and treating cancer | |
KR102665275B1 (ko) | 신규 항인간 CEACAM5 항체 Fab 프래그먼트 | |
AU2018211539B2 (en) | Compositions and methods for cancer imaging and radiotherapy | |
US11452786B2 (en) | Double-labeled probe for molecular imaging and use thereof | |
EP2904013B1 (fr) | Polypeptides de liaison de her3 | |
US20220175975A1 (en) | HER3 Peptides for Imaging and Radiotherapy | |
EP2380597A1 (fr) | Dérivés de cyclopeptide et ses utilisations | |
TWI829893B (zh) | 診斷肺癌的方法 | |
WO2022211051A1 (fr) | Complexe radioactif d'anticorps anti-egfr, et produit radiopharmaceutique | |
US20240207463A1 (en) | Radioactive complex of anti-egfr antibody, and radiopharmaceutical | |
JP2022549258A (ja) | セラノスティックスとして使用するための放射性標識grprアンタゴニスト | |
Dobitz | Oligoprolines as Multivalent Scaffolds for Tumor Targeting | |
EA042953B1 (ru) | Композиции и способы для визуализации и лучевой терапии рака |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
AS | Assignment |
Owner name: THE GENERAL HOSPITAL CORPORATION, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MAHMOOD, UMAR;LARIMER, BENJAMIN;SIGNING DATES FROM 20200625 TO 20201208;REEL/FRAME:055064/0024 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction | ||
AS | Assignment |
Owner name: UNITED STATES GOVERNMENT, MARYLAND Free format text: CONFIRMATORY LICENSE;ASSIGNOR:MASSACHUSETTS GENERAL HOSPITAL;REEL/FRAME:063103/0183 Effective date: 20221110 |
|
AS | Assignment |
Owner name: UNITED STATES GOVERNMENT, MARYLAND Free format text: CONFIRMATORY LICENSE;ASSIGNOR:MASSACHUSETTS GENERAL HOSPITAL;REEL/FRAME:066059/0524 Effective date: 20231206 |